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ABSTRACT OF DISSERTATION 
 
 
SYNTHESIS AND EVALUATION OF UPROUTEOLYSIS UTAURGETING CHIMERAS 
(PROTACs): A POTENTIAL CHEMICAL GENETIC APPROACH TO BREAST 
CANCER THERAPY 
 
The use of small molecules to probe the function of proteins is referred to as 
chemical genetics. The Proteolysis Targeting Chimera (PROTAC) is a chemical genetic 
tool that contains the ligand for a target protein of interest and the recognition motif for 
an E3 ubiquitin ligase attached by a linker. The PROTAC is capable of binding to and 
recruiting specific target proteins to the intracellular degradation system, the ubiquitin 
proteasome system (UPS). While the approach has had success it has not been optimized 
to be used on a broader scale.  
Optimization efforts focused on elucidating the ideal linker length between the 
ligand and the E3-ligase recognition motif, the preferred location for attachment of the 
linker to the two moieties, and the possibility for a dimeric PROTAC comprised of two 
ligands. An estrogen receptor (ER)-targeting PROTAC was chosen as a model for 
optimization attempts as the ER is known to have pathological significance in breast 
cancer. Optimization of the PROTAC technology will not only provide a novel tool to 
probe ER biology, but may also offer a novel approach to breast cancer therapies. The ER 
targeting PROTAC constitute the 17β-estradiol (E2), as the ligand for ER and a 
pentapeptide derived from HIF-1α as the E3-ligase recognition motif, joined by a linker. 
Following the successful synthesis and evaluation of a number of PROTACs, it 
was revealed that an optimum ER-targeting monomeric PROTAC (KC-3) has a spacer of 
16 atoms between the E2 and HIF-1α pentapeptide. The spacer is attached at the C-7α 
position on E2 and at the N-terminus of the HIF-1α pentapeptide. It was also established 
that the PROTAC is capable of targeting the ER for degradation in a proteasome and E3-
ligase dependent manner, which translated to a decrease in the proliferation of MCF-7 
cells with an ICR50 Rsimilar to that of tamoxifen. KC-3, in comparison with E2, displayed 
lower agonistic activity on an ER-regulated downstream target, the progesterone receptor 
(PR).  A dimeric PROTAC more effectively binds and degrades the ER in a proteasome 
dependent manner, suggesting that the dimeric ligand approach may be applied to the 
design of other PROTACs. 
 
KEYWORDS: PROTAC, Chemical-genetics, Estrogen-receptor, breast-cancer, ubiquitin 
proteasome system. 
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CHAPTER 1: OVERVIEW 
 
Traditionally, the roles of proteins in cells have been elucidated using classical 
genetic approaches; while this system has provided powerful tools for investigating 
protein functions, there are several limitations to the classical method (reviewed in 
chapter 2). Thus, a complimentary strategy termed “chemical genetics” has been 
developed, which may shed light in areas where “classical genetics” has constraints. 
Chemical genetics employs small molecules to interrogate the roles of proteins. The use 
of small molecules confers high spatial and temporal control that is difficult to obtain by 
classical genetic approaches. A major advantage of chemical genetic tools over classical 
genetic methods is that chemical genetic tools can be directly translated into new 
therapeutic agents. Thus, a number of approaches have been developed to identify small 
molecules that modulate specific protein functions.  
Recently, a novel small molecule approach termed UPro Uteolysis UTa Urgeting 
Chimeras (PROTACs) has been developed by exploiting an intracellular protein 
degradation system, the ubiquitin-proteasome system (UPS). Since the pioneering work 
by the Crews and Deshaies laboratoriesP [1]P, the PROTAC technology has been developed 
for a number of target proteinsP [2, 3, 4, 5, 6, 7, 8, 9]P, but it has not yet been optimized as a tool 
to be used on a broad scale. This dissertation details an attempt to elucidate an effective 
PROTAC design strategy. The knowledge gained from this research will provide a 
blueprint for the future development of PROTACs targeting a variety of proteins and 
offer some insights into the potential of PROTACs as therapeutic agents. The PROTAC 
is comprised of a ligand specific for a target protein of interest linked to an E3 ligase 
recognition motif (Figure 1.1).  Once bound to the target protein the E3 recognition motif 
is identified and the target protein is ubiquinated and ultimately degraded by the UPS. 
The work set forth in this dissertation utilizes the PROTAC approach to develop a unique 
molecular probe of ER biology and to potentially develop novel therapeutic agents for 
treatment of breast cancer.  
A large subset of breast cancers over- expresses the estrogen receptor (ER) and is 
classified as ER-positive. Due to the high levels of ER in this class of breast cancer, 
therapies (antiestrogens, aromatase inhibitors) aimed at blocking the interaction of ER 
with its natural ligand, 17β-estradiol (E2), have frequently been employed P [10, 11]P.  
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Figure 1.1 The PROTAC 
 
Prolonged antiestrogen treatment however, results in the development of resistance to 
these therapiesP [12]P. One principal concern related to resistance is the fact that most tumors 
maintain expression of functional ERs. However, these ERs are often aberrantly 
regulated; for example, unusual phosphorylation, which causes antagonists to act as 
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agonists P [12, 13, 14]P.  Thus, mere perturbation of ER’s interaction with its ligand is not 
sufficient, and a strategy that selectively knocks-out the ER will be useful for the 
treatment of breast cancer. As such, development of an effective ER-PROTAC may 
provide a novel breast cancer treatment strategy. 
 
Goal: 
 
The goal of this project is to develop an effective PROTAC design strategy as well as 
efficient ER-degrading PROTACs. 
 
Specific aims: 
 
Specific aim 1: Synthesis of PROTACs that target the ER 
The first aim of this study is the synthesis of a number of PROTACs. In earlier 
designs of an ER-PROTAC the attachment of the linker was via an ester linkage. Initial 
(unpublished) data indicated that the linkage was susceptible, in vivo, to esterase activity. 
Therefore, the first attempt at optimization is to replace the ester linkage with a stable 
linkage, such as a C-C linkage, by changing the location of the attachment of the linker 
on 17β-estradiol. The bulk of the optimization work will be focused on the length of the 
linker between the two moieties of the PROTAC to provide an adequate distance between 
the E3 ligase and target protein for optimum ubiquitination. To increase the binding 
opportunity with the target protein, a dimeric ligand PROTAC having two estradiols will 
also be introduced. 
 
Specific aim 2: Determine optimal PROTACs based on their ability to degrade ER in a 
proteasome-dependent manner 
Following the successful synthesis of PROTACs, their ability to specifically 
target the ER for degradation will be evaluated in MCF-7 ER-positive cells. Western 
blotting techniques as well as immunofluorescence will be employed to look at the ER 
status after treatment with PROTACs.  The ICR50 for each compound will also be 
determined. 
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Specific aim 3: Evaluate optimal PROTACs effect on ER regulated genes 
Based on the information gathered from the initial ER screening the optimal 
PROTACs will be tested for the ability to affect downstream targets of ER. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kedra C.Cyrus 2009 
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CHAPTER 2: BACKGROUND 
 
 
2.1  UChemical genetic approach 
 
 
2.1.1 Introduction 
 
     Perturbation of protein function is essential in understanding the role of a 
particular protein in the etiology of a specific disease. Presently, two different approaches 
can be applied to study the function of a protein of interest. One method, termed 
“classical genetics” involves the genetic manipulation of the target protein’s genes with 
subsequent observation of phenotypic changes. The other approach involves the use of 
small molecules to achieve essentially the same result and is termed “chemical genetics.” 
In essence, regulation of protein can occur at three different points; at the genetic stage, 
post-transcriptional stage and at the post-translational stage P [15]P.  
 
2.2  Classical Genetics 
 
Modifications involving the removal or activation of genes for a protein of 
interest are referred to as the “genetic” or “classical genetic” approach P [16]P. Such 
manipulations allow for the observation of phenotypic differences between wild-type and 
altered proteins and ultimately identification of a functional role of the protein in the 
diseased state.  Classical genetics can be divided into two approaches, forward and 
reverse. 
Forward genetics starts with the random mutation (chemical or radiation) of the 
DNA of a wild-type cell/organism, and following mutation the phenotypes of the mutants 
and wild-types are compared. Once a phenotype (growth, behavior or morphological 
change) is chosen, gene mapping is performed to identify the gene responsibleP [17, 18, 19, 20]P. 
Basically, forward genetics function on an “effect to cause” basisP [18, 21, 22]P. On the other 
hand, reverse genetics deals with the targeted deletion of a particular gene, observing 
phenotypic differences when compared to wild-type and eventually delineating the role 
of that specific geneP [23]P. Reverse genetics owes its evolution to the many progresses in 
molecular biology techniques P [17, 23]P. However, one of the major limitations encountered 
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in applying the classical genetic strategy is that of lethality. Deletion of certain genes can 
be fatal to the organism under investigation due to the fact that a particular gene may be 
required for developmental purposesP [24]P. To overcome these problems new strategies 
were implemented such as conditional knock-out/knock-in and siRNA strategies. 
The use of conditional alleles has provided a level of temporal control within the 
field of classical genetics. The gene of interest can be turned on or off at a particular time 
based on certain conditions. Initial attempts to achieve temporal control made use of 
single transgenes that were stimulated by heavy metals, temperature, interferon and 
steroids P[24]P. However, these methods proved unreliable as there were unrelated effects 
related to the induction or low basal activity in the absence of induction P[24, 25]P.  
Eventually a dual transgenic system was adopted that relies on the association of 
two different transgenes, an “effector” and a “target”. The dual transgenic system is 
classified based on the activity of the “effector”. In one case the effector is responsible 
for transcriptional transactivation of the “target” transgene while in the other case, the 
effector is DNA recombinase.  DNA recombinase is site specific, and its action results in 
rearrangement of the target gene resulting in the subsequent activation or deactivation of 
the gene. Among the two most commonly used and established dual systems are the 
Tetracycline regulated (TetR) and Cre/loxp systems representing the transactivation and 
the site specific DNA recombinase systems, respectivelyP [25]P.  
As with conditional knock-out, small interfering RNA (siRNA) technology has 
had a great impact on studies of protein function. Protein silencing by siRNA involves 
double-stranded siRNA having average sizes of around 22 nucleotidesP [26]P. There is two-
nucleotide overhang at the 3’-end, that is specifically recognized by the RNA-induced 
silencing complex (RISC) and a 5’-end that is phorsphorylatedP [27, 28]P. Following 5’-end 
phosphorylation, the siRNA forms a complex with RISC that ultimately leads to the 
release of one strand (passenger strand).  The resulting complex consists of the other 
strand (guide strand) and RISC. This  complex is capable of binding and cleaving 
complimentary mRNA  and silencing its expressionP [26]P.  
Despite the obvious advantages of the siRNA strategy there are a few limitations. 
Among these is the lack of complete knock-down of the protein of interest as compared 
to a genetic knockout; additionally, this method only blocks new protein synthesis and 
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thus, has no effect on the current protein poolP [15]P. Added to the above limitations are the 
lack of temporal control, some reported off-target effects as well as limited in vivo uses 
of siRNAP [15, 17]P.   
 
2.3  Chemical Genetics 
 
The constraints of classical genetic approaches pointed to a need for alternative 
methods that can control protein function in areas where traditional methods may not be 
viable. Chemical genetics is a complimentary tool to classical genetics and affords 
control of protein function at the post-translational level. Chemical genetics is defined as 
the use of small molecules to disturb the function of protein with high temporal and 
quantitative controlP [16, 29]P. Like classical genetics, chemical genetics approaches can be 
classified as forward and reverse. 
Forward chemical genetics employs small molecules to look for phenotypic 
changes in the biological system under examination, and ultimately leads to the 
revelation of the protein that is being affected by the small moleculeP [29]P. In the same way 
classical genetics uses random mutagenesis in its forward approach, chemical genetics 
uses small molecule libraries and  screens for certain phenotypic changes P[18]P. Conversely, 
reverse chemical genetics targets small molecules towards a protein of interest and once 
the interaction is confirmed, the effect of the small molecule against the target is deduced P 
[18, 29, 30]
P.  
 
 
2.3.1  Advantages of chemical genetics  
 
 Chemical genetics has a number of advantages compared to classical genetics. 
Among the many advantages, it is most important to note the high spatial and temporal 
control provided by this strategyP [29, 31]P. Removal or addition of the small molecule can be 
time controlled even in situations where a process is occurring on a short time scaleP [32]P. 
This conditional control is only rarely available in classical genetics and when employed 
often has off-target effects P [23]P.  Moreover, chemical genetics allows for the possibility of 
a “multi-knockout” scenario by merely adding small molecules specific for different 
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targets of interest, a scenario that is not readily accomplished using classical genetic 
methods P [33, 34]P. 
Classical genetic approaches, in essence, remove the entire protein product 
resulting in total loss of function or, in the case of a critical gene deletion, no possible 
characterization of the gene due to lethalityP [32]P. This total loss of protein by the classical 
genetic method makes it difficult to decipher effects that are due to the deletion or effects 
that occur due to a precise function of the proteinP [20, 35]P. Lethality can be avoided using 
the chemical genetic approach by adjusting the dose to sublethal levels, ensuring a partial 
knock-out phenotypeP [36]P.  
With chemical genetics, since the small molecule directly affects the protein 
under study, it can be applied to probe one function of a multifunctional proteinP [37]P. This 
selectivity of function has proven significant in the cases of kinases. Kinases have been 
shown to have different roles owing to their enzymatic and protein scaffold activities. 
The use of small molecule kinase inhibitor allows for blockage of the phospho-transfer 
activity and leaves the protein scaffold activity untouched allowing for the categorization 
of distinct activities which would be lost in the case of gene deletionP [38]P. Tubacin 
provides another example of selectivity of function by a small molecule approach. This 
small molecule selectivity inhibits the tubulin deacetylase activity of histone deactylase 6 
while sparing the histone deacetylase activityP [39, 40]P.  
Knight et al, P [41]P showed an additional advantage of a small molecule approach: 
looking at the specificity of small molecules for certain isoforms of the phosphoinositide 
3-kinases (PI3K) and then deciphering the roles of the isoforms in insulin signaling. A 
small molecule approach may also be effective in studying protein-protein interaction. 
Recently, an inhibitor that binds tumor necrosis factor (TNF-α) and causes dissociation of 
one of the members of the trimer was shown to cause inactivation of TNF-α signaling P 
[42]
P.  
Perhaps one of the most attractive aspects of chemical genetics is its ability to 
simultaneously identify proteins that are “druggable” and develop small molecules that 
target the protein as drug candidatesP [32]P. As it relates to drug development, within the 
field of chemical genetics there are two major requirements. First, the target has to play a 
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decisive role in the progression of the disease. Second, the target protein’s role has to be 
amendable to modulation by a small moleculeP [43]P.  
 
2.3.2  UChemical genetic libraries 
 
In order to conduct chemical genetic studies the first criteria is the formation of a 
small molecule chemical library. A chemical genetic library may take on a number of 
different forms ranging from natural product, natural product-like, tagged libraries,  to 
annotated chemical librariesP [18]P. Following is a brief summary of some of the library 
types employed in chemical genetic studies: 
Natural product libraries - as the name implies these libraries are constructed 
from natural sources like plants, sponges and soilP [20]P. The limitation of a natural product 
library is that isolation and purification of active compounds is laborious and time- 
consuming; even after successful isolation there is the added difficulty of structure 
determinationP [44, 45, 46, 47]P. Despite these limitations, natural products have lent a great deal 
to chemical genetics efforts. Some of the better known natural products used in chemical 
genetics and their targets are rapamycin, which is an immunosuppressant, trichostatin an 
HDAC inhibitor and FK506 which binds FKBP12. 
Natural product-like libraries – these libraries comprise small molecules whose 
structure significantly resembles their natural product counterpartsP [48]P. Because natural 
products are considered “privileged” structures, meaning they contain structural motifs 
that can interface with unrelated targets. Natural products are also considered 
“biologically validated” and as such offer a great starting point for the creation of 
libraries that should have biological activityP [49, 50, 51]P. These libraries can be constructed in 
order to generate derivatives of the natural productP [46, 52, 53, 54, 55]P or to expand the utility 
of a molecule to seek out unknown propertiesP [56]P.  
Tagged libraries – compounds in these libraries must incorporate a tag in the 
molecule and these tags should confer some function to the molecule. Some of the 
functions rendered by tags are: fluorescence, purification, identification, cell-permeability 
and immobilizationP [57]P. Among the better-known tags being utilized in chemical genetics 
is the green fluorescence protein (GFP). Another tag that is in use is polyamide nucleic 
acid (PNA) tags, which specifically bind to certain sequences on DNA. The first 
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successful use of PNA-tag small molecules was used in the exploration for inhibitors of 
cathepsin LP [58]P.  
Diversity oriented synthesis (DOS) – The goal of such a library is to synthetically 
mimic the diversity observed among natural products. In this sense, a library is complied 
of many different types of structures without regard to any particular biological targetP [59]P. 
Among the common methods applied in constructing such a library is the “split-pool/one-
bead-one compound” methodP [45]P. The split-pool method involves the linking of substrates 
having a desired core structure to beads which are then split into different reaction vessels 
and other reactants are added. Once mixed, the beads are pooled and split again repeating 
the procedure until all desired components are addedP [45, 59, 60, 61]P. 
Focused library – In contrast to a DOS library, a focused library builds 
compounds intended to bind to a particular targetP [44]P. A “rational” design is favorable 
when there is a known ligand for a particular protein of interest, as in the case of 
receptors and enzymes P [29]P.  
 
2.3.3  UScreening 
 
Regardless of the type of library constructed, the next step in any chemical 
genetic study is screening; as mentioned previously, screening can be under the banner of 
forward or reverse chemical genetic approaches. When dealing with large compound 
libraries high-throughput screening (HTS) is the standard procedure as it has the ability to 
investigate large numbers of compounds in a short time frame. Single cell systems like 
yeast/bacterial, human and mouse cellsP [62]P.  
 
2.3.4  Forward genetic screening/ phenotype-based screening 
 
Akin to the forward classical genetic methods, this methodology aims to find 
targets that are affected when a collection of small molecules are applied to a test system. 
The effects of the small molecule on a target can be ascertained by looking at phenotypic 
read-outs. Read-outs may include “markers”, which measure the abundance of specific 
proteins as a readout of a global cellular phenotypic effects; functional assays, which 
measures cellular activities including those associated with cell division, metabolism and 
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apoptosis; or microscopic analysis, which looks at the physical nature of the cell or any 
localization events of a particular marker”P [19, 62]P. Perhaps one of the best-known 
compounds to be identified in a phenotype-based screen is FK506, an 
immunosuppressant, identified by researchers in Japan in a screen of natural products 
active against interleukin 2 (IL-2)P [63, 64]P. Later the targets of FK506 were shown to be 
FKBP12 and calcenurinP [65, 66]P. 
One common method employed in phenotypic screening is the cytoblot. Cytoblot 
assay is a high throughput assay that is capable of measuring DNA synthesis and 
posttranslational activities such as phosphorylation. This assay was pioneered in the 
Schreiber laboratoryP [67]P. The assay includes the techniques of western blot and the 
enzyme linked immunosorbent assay (ELISA). In short, whole cells are fixed and 
detected with a specific primary antibody, followed by exposure to horseradish 
peroxidase (HRP)-linked secondary antibody, quantity of product present is detected via 
chemiluminescenceP [67]P. One of the first compound-target interactions to be elucidated via 
cytoblot was the monostrol-motor protein interaction. It was shown that monostrol 
affected a motor protein necessary for spindle bipolarity, but had no effect on tublinP [68]P. 
Other common techniques employed in forward genetic screens involve the use of 
reporter gene assays such as luciferase and automated microscopy P [18, 19]P. 
 
2.3.5  UReverse genetic screeningU  
 
This type of screening looks at the effects of small molecules on the identified 
target of interest. The limitation of the reverse genetic screen is that only a few protein 
targets have known small molecule partnersP [67]P. Nonetheless, in the few cases where a 
reverse genetic approach is feasible it offers tremendous insights into the functions of 
proteins. According to Thorpe, this is the method widely used in pharmaceutical 
companies, where small molecule effectors for proteins of interest are selectively sought P 
[69]
P. There are several techniques employed in reverse genetic screening; however, for the 
purpose of this dissertation only the UPro Uteolysis UTa Urgeting Chimeric (PROTAC) approach 
will be discussed in detail. 
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2.3.6    Proteolysis Targeting Chimeras (PROTACs)  
 
The PROTAC approach is a reverse chemical genetic approach pioneered by the 
Crews and Deshaies laboratoriesP [1]P. While most reverse chemical genetic methods 
perturb protein function simply by binding the target, the PROTAC approach induces a 
chemical knock-out of the target protein. The PROTAC is a chimera having a small 
molecule ligand of a target protein at one end and an E3 ligase recognition motif at the 
other end. Thus, the PROTAC is designed to recruit target protein to E3 ubiquitin ligase 
for polyubiquitination and subsequent degradation by the 26S proteasome (Figure 1.1).   
The first PROTAC developed by Sakamoto et al. provided proof of concept for 
the utility of the technology. Specifically, they developed a PROTAC composed of the 
ligand ovalicin, an angiogenesis inhibitor that binds covalently to methionine 
aminopeptidase-2 (MetAP-2), at one end and the IκBα-derived E3 recognition motif at 
the other end. The IκBα derived peptide ligand is specifically recognized by a Skp1-
Cullin-F box (SCF) E3 ligase, SCFPβ-TRCP [1]P. This study showed that the PROTAC can 
recruit otherwise non-proteasome related, MetAP-2, to the E3 ligase where it is 
ubiquitinated and ultimately degraded by the ubiquitin proteasome pathwayP [1]P.  
Parallel to the success of PROTACs in vitro, many practical issues were raised 
regarding the general utility of the approach.  They included concerns as to whether 
PROTAC would work in cells, be able to target other proteins especially those related to 
disease progression, and target proteins without requiring covalent attachment P[70]P. To 
address such questions, PROTACs targeting the estrogen and androgen receptor, (ER) 
and (AR) respectively, were developedP [70]P. These PROTACs contained the same 
phosphopeptide derived from IκBα that is specifically recognized by SCFPβ-TRCP  [70]P. The 
study proved that the PROTACs were capable of targeting therapeutically relevant 
proteins, in cells without requiring a covalent attachment to the target. However, the use 
of the phosphopeptide renders the PROTACs impermeable to cells and therefore 
microinjection had to be performed in order to deliver the PROTACs to cells P [70]P.  
The cell permeability issues that arose from the use of the phosphopeptide were 
overcome by the development of PROTACs that contain a recognition motif derived 
from HIF-1α. The HIF-1α is specifically recognized by the von Hippel Lindau (pVHL) 
E3 ligase complexP [6, 7, 8]P. Zhang et al. first employed the HIF-1α : pVHL specific 
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interaction to target both ER and MetAP-2 (in this study the term small molecule 
proteolysis inducer [SMPI] was used instead of PROTAC) P [8]P. Furthermore, they showed 
that a pentapeptide derived from HIF-1α is sufficient for recognition by pVHL P[2, 7] P. 
Similarly, Schneekloth et al. designed PROTACs having the HIF1-α derived hepta or 
octapeptides that target FKBP12 and AR. In this study, they added a polyarginine tail to 
further enhance cell permeabilityP [6]P. Using the HIF-1α: pVHL system, additional 
PROTACs that target the arylhydrocarbon receptor (AHR) P [3, 9]P, the ER and AR P [4]P have 
been developed.  
 
2.4   The Ubiquitin-Proteasome System (UPS) 
 
The PROTAC approach exploits an intracellular protein degradation system, the 
ubiquitin-proteasome system (UPS). The UPS is responsible for the selective and specific 
degradation of most proteins in eukaryotic cells, including the degradation of misfolded 
and many signaling proteins.  Destruction of proteins via the UPS is a highly selective 
process and involves two distinct and consecutive steps. The first step is the covalent 
attachment of multi-ubiquitin to a target protein. The second step is the degradation of the 
ubiquitin tagged protein by the 26S proteasome. 
 
2.4.1  U biquitination process  
 
Ubiquitin (Ub) is a highly conserved 76-amino acid polypeptide present in all 
eukaryotic cells which is used to tag proteins for destruction by the UPS.  The process of 
protein ubiquitination involves the actions of three different enzymes referred to as E1 
(activating enzyme), E2 (conjugating enzyme) and E3 (ligase) (Figure 2.2). It is 
interesting to note that ubiquitinated proteins are not always targeted for degradation by 
the proteasome. For example, certain proteins are tagged with one or a few ubiquitins and 
then undergo endocytosis via the lysosomal pathway. Lysine 29 (K29) is believed to be 
responsible for the lysosomal degradation P [71, 72]P. Chain formation on lysine 63 (K63) 
does not appear to be proteolytic and may be associated with DNA repair activities, 
among othersP [72]P.  Nevertheless, for proteins that are fated for destruction, a highly 
selective series of enzymatic events have to occur. First, the C-terminal glycine residue 
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(Gly76) on Ub is activated by the E1 activating enzyme in an ATP dependent manner. 
Until recently it was believed that only one E1 existed, but the latest reports seem to 
suggest that there may be additional E1s P[73, 74]P. The activation reaction involves the 
formation of a Ub-adenylate with the release of pyrophosphate (PPi) from ATP. The 
activated Ub is then transferred to a cysteine residue on the E1 with the concomitant 
liberation of AMPP [75, 76, 77]P. The result of this reaction is the formation of a high energy 
E1-thiol-ester-Ub intermediate that is then transferred to an E2 conjugating enzyme 
(Figure 2.2)P [75, 76, 77]P.  
In comparison to the E1 enzyme, there are known to be a number of E2s. As 
many as eleven have been reported in the yeast genome and that number is thought to be 
greater in higher organisms P [78]P. The E2s are referred to as the Ub carrier proteins or Ub 
conjugating enzymes as they accept the activated Ub from E1 and facilitates its 
attachment to the target protein in conjunction with E3s (Figure 2.2). The E2s may serve 
as a bridge between the target protein and an E3 or may transfer the Ub to an E3, which 
will subsequently tag the protein. 
The E3s are responsible for the specific recognition of a particular substrate and 
can be either a protein or a protein-complex P [79]P. The E3 reaction involves two events,  the 
Ub signal dependent binding of the E3 to substrate and  the covalent attachment of Ub to 
the target proteinP [78]P. Two of the most widely studied classes of E3s are the HECT 
(Homologous to the E6-AP C-Terminus)P [80]P domain E3s and the RING (Really 
Interesting New Gene) finger domain E3s.  
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Figure 2.2 The Ubiquitin - Proteasome System 
 
16 
 
 
The HECT domain E3s has a conserved cysteine residue to which Ub from the E2 
is transferred, forming another high energy thiol ester bondP [81]P. These E3s then transfer 
the activated ubiquitins to a lysine residue, often lysine-48 (K48), on the substrate. A 
member of the HECT E3 family is NEDD4 that targets the sodium channel in the kidney 
epitheliumP [82]P. Unlike HECT E3s, the RING finger family of E3s acts as a bridge 
between the substrate and E2. They do so by binding to both the E2 and the substrate 
thereby, bringing the two within a proximity where the E2 is able to directly transfer Ub 
to the K48 residue of the substrateP [83]P. RING E3s are monomers or homodimers 
containing both the RING finger domain and the substrate recognition site in one 
molecule. Examples include mdm2, which targets p53P [84, 85]P and parkin, which targets 
synaptic vesicle-associated protein, CDCrel-1P [86, 87]P.  A number of RING E3s are part of 
larger multisubunit complexes such as the SCF complex, which is involved in the 
degradation of IkB P [88]P, the APC (Anaphase Promoting Complex, responsible for 
degrading cell cycle regulatorsP [89]P and the VBC (von-Hippel Lindau(VHL)-Elongins B 
and C)-Cul2-Rbx1 E3 ligase complex associated with the degradation of Hypoxia 
Inducible Factor (HIF)-1α P [90, 91, 92]P.  
 
2.4.2   UVBC-Cul2-Rbx1 E3 ligase complex and HIF-1α 
 
The unique interaction of HIF-1α with the VBC E3 ligase has been well 
characterized. HIF is important for normal development and plays a pivotal role in 
pathophysiological responses to low oxygen (hypoxic) conditions, as well as in tumor 
growth and angiogenesis P [93]P. HIF is a heterodimer consisting of α and β subunits that 
binds to DNA under hypoxic conditions. The β subunits are constitutively expressed 
whereas the alpha subunit is highly regulated. Under normal oxygen (normoxia) 
conditions, the alpha subunits are rapidly targeted for polyubiquitination by pVHL and 
subsequently degraded by the proteasome.  
pVHL is a tumor suppressor protein whose mutation is associated with the 
development of VHL disease, a hereditary cancer characterized by the presence of highly 
vascularized tumorsP [94]P. pVHL binds to a specific region on HIF-1α known as the 
oxygen-dependent degradation domain (ODD) P [95, 96]P. There are two distinct regions that 
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can operate independently of each other: one at the C-terminal (C-ODD) and the other at 
the N-terminal (N-ODD)P [97, 98]P. The interaction of pVHL at these domains is regulated by 
the hydroxylation on specific proline residues within the ODD proline 402 (Pro 402) in 
the N-ODD and proline 564 (Pro 564) in the C-ODD P [95, 99]P. Experiments conducted using 
various peptide lengths within the ODD indicated that the C-ODD region in HIF-1α is 
important for the binding of pVHL, while the N-ODD region only increases binding 
slightlyP [100]P. Further, mutation studies demonstrated that there is a highly conserved motif 
containing a proline residue (Pro-564) and this motif is critical for the interaction with 
pVHL. Later, it was shown that hydroxylation of the proline initiates the ubiquitination 
and degradation of HIF-1αP [99]P. In the present studies, this interaction has been exploited 
in designing PROTACs that target the ER for proteasomal degradation. 
 
2.4.3   UThe Proteasomes 
 
The 26S proteasome is a hollow cylindrical-shaped mega structure (2.4 MDa) 
containing a 20S subunit referred to as the catalytic core and the 19S regulatory subunitP 
[101]
P (Figure 2.2). There are two types of proteasomes, the regular (or constitutive) 
proteasome and the cytokine-inducible immunoproteasome. The immunoproteasome is 
thought to be associated with the generation of MHC class I antigensP [102]P. 
The 20S catalytic subunit consists of two sets of heptameric α and β subunits 
arranged as four stacked rings. The two outer rings are each made up of seven α subunits 
while the two inner rings each contain seven β subunitsP [103]P. Three of the β subunits, β1, 
β2 and β5, are catalytically active and their proteolytic activities are uniqueP [79]P. β1 
displays caspase-like (C-L) activity, cleaving after acidic residues, β2 cleaves after basic 
residues (trypsin-like activity, T-L) and β5 cleaves after bulky hydrophobic residues 
(chymotrypsin-like activity, CT-L) P [104]P. In response to γ-interferon signaling these β 
subunits are replaced with three alternative subunits: β1 replaced with β1i/LMP2, β2 with 
β2i/MECL-1/LMP10 and β replaced with β5i/LMP7P [105]P to form the immunoproteasome.  
As it relates to the function of the α subunits, it has been shown that the N-termini 
of the α subunits block entry of protein substrates to the proteolytic cavity thus acting as a 
gate to prevent unwanted degradationP [106]P. The 20S proteasome only becomes accessible 
18 
 
upon the binding of the 19S regulatory subunit. The 19S regulatory particle consists of a 
9-protein lid for polyubiquitin binding, and a 10-protein base that interacts specifically 
with the α ring. The 19S base binds to and displaces the N-terminal of the α subunits P [107]P, 
wheras the 19S-lid regulatory particle is involved in the recognition, binding and 
deubiquitination of polyubiquitinated substrates P[108, 109, 110, 111]P. The 19S-base contains 
several ATPases and deubiquitinasesP [112]P. Once the substrate enters the catalytic core it is 
degraded into smaller peptides.  
 
2.5   Estrogen receptors (ER) and Breast Cancer 
 
 
2.5.1   UEstrogen receptor (ER) 
 
The estrogen receptors (ER) belong to the family of nuclear receptors, which is 
one of the largest classes of proteins having over 70 known members. The ER is more 
specifically referred to as a steroid hormone nuclear transcription factor. Currently, two 
types of estrogen receptors exists ERα and ERβ. The ER (ERα) was cloned in 1986P [113]P 
approximately 40 years after Jensen indicated the possible role of a receptor that 
specifically binds 17β-estradiol (E2) P [10, 11, 114]P. The second receptor ERβ was cloned in 
1996P [115]P.  
The ER contains a number of functional domainsP [116, 117, 118, 119]P as depicted in 
Figure 2.3.  There is an N-terminal A/B domain that is not well conserved among the 
steroid receptors. Within the A/B domain is a transactivation function (AF-1) responsible 
for ligand-independent transcriptional activation. The C domain comprises the DNA 
binding domain, which is the most highly conserved domain within the nuclear receptor 
family. The DBD is responsible for the high specificity, high affinity binding of the ERs 
to their estrogen responsive elements (EREs) P [120, 121, 122]P. Within the DBD there are two 
zinc finger motifs. While there are a number of similarities among zinc fingers within the 
nuclear receptor family, mutagenesis studies indicate that one of the zinc fingers lends 
specificity to the individual receptors by binding to specific residues in the major groove 
of DNA; the other zinc finger works to stabilize the aforementioned interactionP [123, 124]P. In 
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addition to the DNA binding domain the C domain also contains a dimerization 
functionality as well as a nuclear localization signalP [121, 125, 126]P.  
 
 
 
 
 
 
 
 
 
Figure 2.3 The functional domains of the estrogen receptor (ER): DBD- DNA 
binding domain, LBD- ligand binding domain, AF-1, 2 (transcription activation function 
1 and 2). 
 
 
 
The D domain is a non-conserved, hydrophilic domain that acts a hinge between 
the DBD and the ligand binding domain (LBD). This domain may direct the DNA-
binding activities of the receptor while the hinge region may also play a role as an anchor 
for co-repressor proteinsP [10, 122, 127, 128]P. The ligand binding domain (LBD) is located in the 
C-terminal E region which contains a hydrophobic pocket formed as a result of 12α 
helices; the hydrophobic pocket is important for ligand bindingP [128, 129, 130]P. The LBD is 
less well conserved in comparison to the DBD. Within the E region there is also a ligand-
dependent dimerization function, a ligand-dependent nuclear localization signal, heat 
shock protein 90 (HSP90) binding utility and another activation function (AF-2), which is 
ligand-dependentP [128, 130]P. The F region at the C terminal domain is involved in a number 
of activities including the selection of agonists or agonists, crosstalk between other 
signaling pathways, regulation of proteasomal degradation and possible blockade of 
dimerizationP [131, 132, 133, 134]P. 
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It must be noted that while the DBD of ERα and ERβ are almost identical (95% 
amino acid identity), and their LBDs are moderately identical, approximately 56%, while 
they differ markedly in their AF-1 (around 21% amino acid identity) P [135, 136]P; the AF-1 of 
ERβ seems to be inconsequential in regulating reporter gene expressionP [137]P. Additionally 
the hinge and the F region are not conserved among the receptorsP [138]P. The ERs also 
differ in their tissue distribution. ERα is predominantly expressed in the breast, vagina 
and uterus while ERβ is more highly expressed in the gastrointestinal system, central 
nervous system, lungs, cardiovascular system, immune system and bone, but is not highly 
expressed in breast tissuesP [135]P. In certain breast cancers, the ERα is over expressed; 
therefore these cancers are termed ER-positive or hormone sensitive.  
 
2.5.2   UMechanisms of action of ERsU  
 
The estrogen receptor is a member of the ligand activated transcription factor 
family. In response to ligand binding, the ER  binds to EREs,  initiating transcription of 
target genes P[139, 140]P. The cellular localization of the unliganded ER has been 
controversial and it seems that the location of the ER plays a role in ER actions. It is 
thought that the unliganded ER predominately resides in the nucleus, but there is also a 
pool of ERs located in the cytoplasm and at the membranes P [139, 141, 142, 143]P. 
 
Genomic actions of ER 
In the “classical or genomic” mechanism, E2 diffuses through the membrane and 
binds to ER, resulting in a conformational change of the ER that allows it to dissociate 
from chaperones, dimerize and bind to the ERE on the target gene’s promoter. Once 
bound to the ERE, AF-1 and AF-2 are responsible for recruiting co-activators from the 
p160 family, steroid receptor co-activators 1, 2 and 3 (SRC1,2,3). Other factors 
responsible for chromatin remodeling, that interact with the general transcription 
machinery in order to initiate transcription of the target genes are also recruitedP [144]P. 
Some of the genes transcribed via the ER genomic action include, trefoil factor 
(pS2/TFF1) and vascular endothelial growth factor (VEGF) P [145]P. 
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Figure 2.4 Mechanism of ER actions 
 
 
Nongenomic actions 
ERs can also act independently of ERE binding. This non-genomic action of the 
ER occurs via protein-protein interactions with other transcription factors. Approximately 
35% of target genes are transcribed in this mannerP [145]P. For example, ER action through 
AP-1 activation is responsible for the transcription of such genes as insulin growth factor-
1 (IGF-1), cyclin D1 and collagenase P [145, 146, 147]P. Opposite effects at AP-1 sites have been 
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indicated for ERβ P [148, 149]P. ER also interacts via a non-classical mechanism with ER- 
specific protein-1 or stimulating protein-1 (SP-1) to mediate transcription of target genesP 
[145, 150]
P. Interaction at SP-1 sites involves the complex binding to GC- rich regions within 
the promoters of target genes enabling transcription of such genes as retinoic acid 
receptor 1α (RXRα), insulin growth factor binding protein -4, low-density lipoprotein 
(LDL) receptor and cathepsin P [151, 152, 153]P.  
 
Non-genomic actions 
Membrane or cytoplasmic ERs are also believed to be responsible for the rapid 
non-classical/ non-genomic actions of ER. In this case, ligand binding to these receptor 
pools result in the activation of a number of signaling pathways.  One such example is the 
mitogen activated protein kinase pathway (MAPK) P [154, 155]P. Estrogen bound membrane 
ER has also been shown to activate the insulin-like growth factor receptor-1(IGF-1R) and 
epidermal growth factor receptor (EGFR) cell signaling cascadesP [12, 156]P.  
 
2.5.3   U ER-positive breast cancer and treatment 
 
Breast cancer is the second leading cause of cancer death among women in 
industrialized countries.  According to the 2009 cancer statistics an estimated 192, 370 
women will be diagnosed with breast cancer and over 40, 000 will die from the disease P 
[157]
P. Approximately 70% of breast cancer diagnosed is ER-positive. The length of 
exposure to estrogen has been shown to play a role in increasing the chance of 
developing breast cancer.  Most of the genes that are upregulated by the ER are involved 
in proliferation and as such have a direct effect on the progression of breast cancer P [158]P.  
Thus, current breast cancer therapies aim to inhibit the action of the ER by blocking the 
production of E2 (eg. aromatase inhibitors) P [159, 160]P or blocking the binding of estrogen to 
the ER (eg.  antiestrogens)P [161, 162, 163, 164, 165, 166]P .  
One of the oldest and most widely used antiestrogen is tamoxifen (Figure 2.5). 
Tamoxifen is classified as a selective estrogen receptor modulator (SERM) having 
antagonist activity in the breast, but agonist activity in the uterus and bone P [167, 168]P. It has 
been shown that the binding of tamoxifen to the ER leads to a conformational change that 
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is different from E2 bindingP [12]P. Specifically, the binding of tamoxifen within the ER’s 
binding pocket results in a conformational change that results in the pocket not being 
sealed properly. This conformational change deters the binding of coactivators resulting 
in the inactivation of AF-2 function. The inhibition of AF-2 function prevents 
transcription of genes that are dependent of AF-2-ER functionality P [169]P. The breast tissue 
is reliant on AF-2-ER mediated gene transcription, whereas the uterus is reliant on the 
ER-AF-1 function; this is why tamoxifen acts as an antagonist in breast, but as an agonist 
in the uterus, where the AF-2 function is not important P [170, 171]P. 
Tamoxifen, by virtue of its SERM nature, has been linked to an increase in the 
chances of developing endometrial cancerP [172]P. The main problem with Tamoxifen and 
other antiestrogenic compounds, as well as aromatase inhibitorsP [173]P, is the eventual 
development of resistance after prolonged use. Close to 100% of patients with metastatic 
disease and about 40% of patients receiving adjuvant therapy succumb to resistance and 
eventually die from the diseaseP [12]P.  There have been several mechanisms proposed for 
the development of resistance to these therapies including, increased ER-HER2 crosstalk P 
[174, 175]
P; elevated levels of EGF, responsible for mediating autocrine growth pathways in 
resistant cellsP [176]P as well as increased phosphorylation of  Ser 118 on the ERP [13]P. 
Phosphorylation at Ser 305 has recently been implicated in the causation of resistance as 
wellP [14]P. It is important to note that loss of ER may not be a factor in development of 
resistance as both tamoxifen-resistant and primary breast tumors retain high levels of ER 
and is affected by pure antagonists P [176, 177]P.  
Another antiestrogen, termed a pure antagonist, is Faslodex® (ICI182,780).  At 
the time of its discovery, ICI182,780 displayed no estrogenic activity and was developed 
as an alternative second line therapy to treat patients that were no longer affected by 
tamoxifen treatment P [178]P. While its mode of action is not clearly understood, ICI182,780 
seem to cause a down regulation of the ERP [179]P. Recent studies seem to suggest that 
ICI182,780 may not be a pure antagonist after all, as it displays agonist activity in 
Hippocampal Neurons P [180]P. While the effect is a positive one, there might be other yet 
undiscovered agonistic activities of this drug that may have negative impacts. 
Given the role of ER in the progression of breast cancer, alternative methods are 
needed to delineate unknown roles or unknown targets that may be associated with the 
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ER. Thus, the employment of a PROTAC that selectively knocks-down the ER is 
proposed as a novel probe to elucidate ER biology. In addition the PROTAC strategy 
may provide a new therapeutic candidate for treating ER-positive breast cancers. 
 
 
Figure 2.5 Structures of Estradiol (E2) and ER antagonists  
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CHAPTER 3: CHEMISTRY- SYNTHESES OF PROTACs 
 
 
3.1  Introduction 
 While the PROTAC technology has been developed to target proteins for 
degradation and may be a valuable tool to investigate protein functions, a detailed 
PROTAC optimization strategy has never been explored.  As such, the main objective of 
this project is to optimize the PROTAC technology for broad applications. The ER 
targeting PROTAC was used as the model in this optimization effort since the first 
generation of cell permeable PROTACs were developed based on ER-targeting strategy. 
In addition, the ER is the main therapeutic target for breast cancer therapy and 
optimization of a PROTAC that specifically targets the ER may pave the way to develop 
a novel ER antagonist that acts differently from any other ER antagonists clinically 
available. The information gathered from this optimization study may also be useful for 
the design of PROTACs that target other proteins. 
 The first generation ER targeting PROTAC (Figure 3.1) involved the 
attachment of a linker at the O-17 position on E2, the natural ligand of the ER (Figure 
3.1). The successful development of the first ER targeting PROTAC provided proof of 
concept for targeting the ER by this approach; however, while this PROTAC was able to 
cause degradation of the ER in vitro, the ester linkage proved to be problematic in initial 
in vivo studies. The linkage was apparently cleaved off as a result of intracellular esterase 
activity resulting in tumor growth (unpublished data).   
In this current study, three main areas were focused on to improve the PROTAC:  
First, in order to address the issue of linker cleavage, the ester linkage was replaced with 
a carbon-carbon linkage through the C-16 and C-7 positions of E2 (Figure 3.1). Second, 
PROTACs were synthesized with varying lengths, in order to determine an optimal 
distance between E3 ubiquitin ligase (pVHL) and the protein of interest (ER). Third, a 
dimeric PROTAC having two estradiols at both ends of the pVHL recognition motif was 
developed in order to increase the chances of recruiting the ER for ubiquitination and 
ultimately degradation. 
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In this chapter the synthetic routes, reaction details and structural analysis of 
intermediates leading up to and including PROTAC synthesis are presented.  
 
 
Figure 3.1 Structure of the original ER-PROTAC (E2-Penta): highlighting the O-17 
ester linkage and the C-16 and C-7 locations for C-C bond formation. 
 
 
General: Unless otherwise noted, all reactions were carried out under nitrogen or 
argon in freshly distilled solvents, oven-dried glassware. Reagent grade solvents were 
used. Tetrahydrofuran (THF) was distilled from sodium/benzophenone. Methylene 
chloride (CHR2RClR2R)R Rwas distilled from calcium hydride. Anhydrous diethyl ether was 
purchased from Fisher and used without further distillation. All other reagents were 
purchased from Sigma-Aldrich and used without further purification. Peptides were 
purchased from Advanced Chem Tech (Louisville, KY).  Reactions were monitored by 
TLC using E. Merck 60F254 pre-coated silica gel plates. Flash column chromatography 
was performed using E. Merck silica gel 60 (particle size 0.040-0.063mm). P1 PH NMR 
spectra were recorded on a Varian 300MHz or 500MHz spectrometers. Mass spectral 
analyses were carried out by the University of Kentucky Mass Spectrometry Facility. 
 
3.2 UpVHL recognition motif derived from HIF-1α 
 
One of the components of the PROTAC is the degradation signal derived from the 
HIF-1α protein. The amino acid sequence recognized by pVHL consists of an (ODD) 
containing the highly conserved sequence (Met-Leu-Ala-Pro-Tyr-Ile-Pro-Met). In 
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previous work it was shown that a pentapeptide derived from HIF-1α ODD domain is 
sufficient to be recognized by pVHL P [7]P.  
The pentapeptide was synthesized following conventional peptide synthesis 
approaches. Briefly, for pentapeptide-1, the synthesis began with the coupling of a C-
terminal protected isoleucine to a tyrosine protected at both its N-terminal and its 
hydroxyl with Fmoc (9-fluorenyl-methoxy-carbonyl) and tertiary-butyl (t-Bu) 
respectively, the coupling reagents HBTU (2-(1H-Benzotriazol-1-yl)-1,1,3,3-
Tetramethyluronium hexafluorophosphate) and HOBt (N-Hydroxybenzotriazole), along 
with DIPEA (N,N-Diisopropylethylamine) as a base in CHR2RClR2R. Following successful 
coupling, the Fmoc group was removed with 20% piperidine in DMF (N,N-Dimethyl 
formamide) and the process was repeated with the remaining Fmoc-protected amino 
acids to give pentapeptide-1 (Figure 3.2). t-Bu protecting group on tyrosine was either 
removed prior to or after full assembly of the PROTAC. A mutant pentapeptide 
(pentapeptide-2, Figure 3.2) containing nor-leucine in place of the hydroxyproline residue 
was also synthesized following a similar procedure described above; this will serve as a 
negative control for pentapeptide-2. In order to study whether linker attachment to the C- 
or N-terminus of the pentapeptide is important for PROTAC activity, an additional 
pentapeptide that was protected at the N-terminal with a benzyloxycarbonyl (cbz/Z) 
group and a free carboxylic acid at its C-terminus was also synthesized (Figure 3.2).  
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Figure 3.2: Structures of pentapeptide-1 to 3 
 
29 
 
 
3.3 USynthesis of C-16α PROTACs  
 
One of the primary goals of this project was to synthesize a PROTAC that had a 
less labile linkage by eliminating the ester linkage and adding hydrolytically stable C-C 
bond. The task was to find a place on E2 that will allow for attachment of the linker 
without disrupting the E2- ER interaction significantly. Another critical issue with the 
original ER-targeting PROTAC was the loss of the 17-OH which was used attach the 
linker. It has been reported that the OH is important for the binding activity of E2 to ER P 
[181]
P; therefore, any modification that can spare the hydroxyls is most desirable in 
designing an ER targeting compound based on the E2. Derivatization at the C-16α 
position on E2  has been previously reported in the construction of a Geldanamycin 
tagged E2 compound that maintained good E2-ER interaction P [182]P.  
In order to attach the pentapeptide to the C-16α position and extend the length of 
the linker attaching the two different moieties a “handle” had to be placed on the E2 that 
would allow for further extension. A scheme, (Scheme 3.1), similar to the one reported 
in P [182, 183]P was followed for synthesis of a “free amine handle” attached to the C-16α 
position of E2. The scheme allowed for the formation of the desired α-alkylation at the C-
16 position, a stereochemistry that is important for the high binding affinity to the ERP 
[184]
P. The handle, can be further extended via amide bond formation.  
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Scheme 3.1- Synthesis of C-16α handle 
 
 
 
 USynthesis of C-16α PROTACs K-1 and K-2 
 Following the successful synthesis of the free amine handle the length was 
further extended using glycine, and an eight carbon linker, disuccinimidyl suberate 
(DSS). The pentapeptide was then attached to give the fully assembled protected 
PROTACs, after deprotection of protecting groups the C-16 PROTACs were isolated as 
K-1 and K-2 (Scheme 3.2). 
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Scheme 3.2 synthesis of C-16α PROTACs K-1 and K-2 
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UReaction details and NMR data for the synthesis of C-16α PROTAC’s handle 
 
Compound 2:  Estrone (1) (4.00 g, 0.0148 mol) and imidazole (3.00 g, 0.044 mol) were 
dissolved in 40 mL (CHR2RClR2R) and 15 ml DMF. tert-Butyldimethylsilyl chloride 
(TBDMS-Cl) (6.70g, 0.044mol) was added, and the solution was stirred at room 
temperature, after 2 hours the solution was filtered through filter paper and solvent 
removed, the residue was dissolved in CHR2RClR2R and column chromatography was 
performed using (5:1 hexanes:ethyl acetate (Hex:EtOAc)) to yield a white solid (5.62 g, 
99%). 
P
1
PH NMR (CDClR3, R500 MHz): δ 0.19 (s, 6H), 0.91 (s, 3 H), 0.98 (s, 9H), 2.84-2.87 (m, 
2H), 6.57 (d, 2.5 Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1 H), 7.13(d, J = 8 Hz, 1H) 
 
Compound 3: Under nitrogen, dry THF (6 mL) was added to a flask containing (2) 
(400.0 mg, 1.04 mmol) and the solution was cooled to 0 °C. Lithium diisopropylamide 
(LDA) (0.80 mL, 1.45 mmol) was then added (drop-wise) and the solution was stirred for 
an additional 0.5 h at 0 °C. The reaction was then cooled to -20 °C using an external bath 
(sodium chloride (NaCl), ice), and electrophile (1,4 dibromo-2-butene) (440.0 mg, 2.08 
mmol, in 1 mL of THF) was added (drop-wise). The reaction mixture was stirred at -20 
°C for an additional 4 hrs, water was then added and mixture was extracted with three 50 
ml portions of EtOAc. The organic phase was washed with brine and dried over sodium 
sulfate (NaR2RSOR4R). Following filtration and solvent removal, the residue was dissolved in 
CHR2RClR2R and column chromatography was performed using (10: l Hex: EtOAc) to give a 
thick yellow oil. Reaction was repeated 4 times with the same amounts to yield (3) (1.2 g, 
45%). 
P
1
PH NMR (CDClR3R, 500 MHz):  δ 0.19 (s, 6 H), 0.96 (s, 3 H), 0.98 (s, 9 H), 2.82-2.85 (m, 2 
H), 3.95 (d, J = 6.6 Hz, 2 H), 5.74 – 5.78 (m, 2 H), 6.57 (d, J = 3 Hz, 1 H), 6.63 (dd, J = 
8.5, 2.5 Hz, 1H), 7.12 (d, 1 H, J = 8.5 Hz, 1 H).  
 
Compound 4: Sodium azide (NaNR3R) (520 mg, 7.64 mmol) was added to a flask 
containing (3) (960 mg, 1.91 mmol) and the contents were dissolved in THF (25ml), 2 ml 
of water and 2 ml DMSO. The mixture was stirred at room temperature for 2 hrs after 
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which, water was added and extraction performed with EtOAc. The organic phase was 
washed with brine and dried over (NaR2RSOR4R). Following filtration and solvent removal, 
residue was dissolved in CHR2RClR2R and column chromatography was performed (10: l Hex: 
EtOAc) to give (4) as a pale yellow oil (889 mg, 96 %). 
P
1
PH NMR (CDClR3R, 300MHz): δ 0.19 (s, 6 H), 0.96 (s, 3 H), 0.98 (s, 9 H), 2.83 (m, 2H), 
3.73 (d, J = 6.3 Hz, 2 H), 5.47-5.80 (m, 2 H), 6.56 (d, J = 2.4 Hz, 1H), 6.62 (dd, J = 8.3, 
2.4 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1 H). 
 
Compound 5:  Methanol (MeOH) was added to (4) (510 mg, 1.06 mmol) and cooled to 0 
°C, after 10 min sodium borohydride (NaBHR4R) (120 mg, 3.19 mmol) was added and 
reaction stirred for an additional 2.25 hrs. MeOH was removed under reduced pressure, 
water was added and EtOAcR Rwas used for extraction. The organic fraction was washed 
with brine and dried over (NaR2RSOR4R). Product was isolated as a white solid (250 mg, 49%) 
following column chromatography (10: l Hex: EtOAc).  * Attempts to simultaneously 
reduce the azide and ketone using LAH were unsuccessful; therefore sequential reduction 
steps were employed: NABHR4R- ketone reduction and LAH-azide reduction. 
P
1
PH NMR (CDClR3R,R R300MHz) δ 0.19 (s, 6H), 0.82 (s, 3 H), 0.99 (s, 9H), 2.80 (m, 2 H), 
3.33 (d,  J = 7.8 Hz, 1H), 3.74 (d, J = 6.6 Hz, 2H), 5.56-5.88 (m, 2 H), 6.55 (d, J = 2.7 
Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1 H), 7.12 (d, J = 8.1 Hz, 1H). 
 
Compound 6: (5) (250 mg, 0.52 mmol) was dissolved in dry THF (15ml) and then 
cooled to approximately -10°C. Excess lithium aluminum hydride (LAH), (100 mg, 2.60 
mmol) was slowly added and the reaction was stirred for 2 hours. Reaction was then 
extracted with CHR2RClR2R dried over NaR2RSOR4R and purified via column chromatography 
(95:5 CHR2RClR2R: MeOH), (6), (159mg, 67%) was obtained as white solid. 
P
1
PH NMR (CDClR3R, 300 MHz) δ 0.19 (s, 6H), 0.82 (s, 3 H), 0.98 (s, 9H), 2.78 - 2.80 (m, 2 
H), 3.21-3.28 (m, 3 H) 5.58-5.63 (m, 2 H), 6.55 (d, J = 2 Hz, 1 H), 6.61 (dd, J = 8.1, 2.4 
Hz, 1 H), 7.12 (d, J = 8.1 Hz, 1H). 
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UReaction details NMR AND Mass spectrometry data for the synthesis of C-16α PROTACs 
K-1 and K-2 
 
Compound 7:  Fmoc-Gly-OH (107mg, 0.360mmo1), HBTU (170 mg, 0.45 mmol) and 
HOBt (69 mg, 0.45 mmol) was added to a flask containing the free amine (6) (136 mg, 
0.30 mmol). The reagents were dissolved in CHR2RClR2 Rand excess DIPEA (310μl) was 
added. The reaction was stirred at room temperature overnight. Column chromatography 
was performed using (1:1 Hex: EtoAC) to yield (7), (105 mg, 47%) as a clear oil. 
P
1
PH NMR (CDClR3R 500 MHz) δ 0.19 (s, 6H), 0.79 (s, 3H), 0.98 (s, 9H), 2.78 – 2.81 (m, 
2H), 2.82 (s, 4H), 3.25 (d, J = 7 Hz, 1H), 3.77-3.89 (m, 4H), 4.23 (t, J = 6.7 Hz, 1H), 4.43 
(d, J = 7 Hz, 2H), 5.47 - 5.70 (m, 2H), 6.27 (t, J = 5.4 Hz, 1H), 6.55 (d, J = 2.4 Hz, 1H), 
6.62 (dd, J = 8.5, 2.4, 2.7 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1H),7.30 – 7.33 (m, 2H),  7.39 – 
7.42 (m, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.77 (d, J = 7.5 Hz, 2H)  
 
Compound 8: 20% piperidine in DMF (1.5 ml) was added to (7) (105mg, 0.143mmol) 
and the reaction was stirred at room temperature for 40 mins. Solvents were removed 
under high vacuum and column chromatography was performed using (95:5 CHR2RClR2R: 
MeOH) to remove by products. The column was washed with MeOH to isolate (8) 
(49mg, 67%) as a white solid. Free amine confirmed by Kaiser test. 
 
Compound 9: Disuccinimidyl suberate (DSS) (70.0 mg, 0.191 mmol) was added to a 
flask containing (8) (49mg, 0.095mmol) and the contents were dissolved in DMF (2.5 ml) 
and stirred at room temperature overnight. DMF was removed under high vacuum and 
(95:5 CHR2RClR2R: MeOH) was used to purify the product via column chromatography. (9) 
(27mg, 38%) was isolated as an oil.  
P
1
PH NMR (CDClR3R 300 MHz) δ 0.18 (s, 6H), 0.80 (s, 3H), 0.97 (s, 9H), 2.61 (t, J = 7.2 Hz, 
2H), 2.78 – 2.84 (m, 6H),  3.27 (d, J = 7.2 Hz, 1H), 3.75-3.81 (m, 2H), 3.90 (d, J = 5.4 
Hz, 2H), 5.44 - 5.70 (m, 2H), 6.33 (t, J = 5.4 Hz, 1H), 6.48 (t, J = 4.8 Hz, 1H),  6.55 (d, J 
= 2.4 Hz, 1H), 6.62 (dd, J = 8.5, 2.7, 2.4 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1H)  
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Compound 10: Pentapeptide-1(no t-Bu), (26.0 mg, 0.035 mmol) was added to (9) (27.0 
mg, 0.035 mmol), dissolved in DMF (2 ml) and stirred under NR2R overnight at room 
temperature. Following removal of DMF under high vacuum, (95:5 CHR2RClR2R: MeOH) was 
used to purify product as a white solid (22.5 mg, 47%).  
P
1
PH NMR (CDClR3R 500 MHz) δ 0.18 (s, 6H), 0.79 (s, 3H), 0.80-0.84 (m, 6H), 0.89-0.93 
(m, 6H), 0.97 (s, 9H), 2.78 – 2.81 (m, 2H),  3.11 (dd J = 7, 3 Hz, 2H), 3.26 (d, J = 7 Hz, 
1H), 3.55 (dd, J = 10.7, 2.7 Hz, 1H), 3.70-3.81 (m, 4H), 3.85 (d, J = 6 Hz, 2H), 4.36 – 
4.55 (m, 6H), 4.60 (t, J = 7 Hz, 1H), 5.13 (s, 2H), 5.45 - 5.49 (m, 1H), 5.66 – 5.69 (m, 
1H),  6.54 (d, J = 2.5 Hz, 1H), 6.60 (dd, J = 8.5, 2.5,  Hz, 1 H), 6.87 (d, J = 8.5 Hz, 2H), 
6.95 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H),  7.13 (d, J = 6.5 Hz, 1H), 7.30 – 7.38 
(m, 6H), 7.39 (d, J = 7 Hz, 1H), 7.55 (d, J = 7.5 Hz, 1H)  
 
K-1: To obtain K-1 the TBDMS protecting group was removed. THF (1ml) was added to 
(10) (22.5 mg, 0.016 mmol), followed by tertiary butyl ammonium fluoride in THF 
(TBAF) (14 μl, 0.048 mmol) and reaction was stirred at room temperature for 20 mins. 
Column chromatography was performed using (95:5 CHR2RClR2R: MeOH) initially and then 
increasing MeOH concentrations to isolate K-1 (20.6 mg, 100%) as a white solid. 
P
1
PH NMR (CDClR3R 300 MHz) δ: 0.79 (s, 3H), 0.80-0.84 (m, 6H), 0.89-0.93 (m, 6H), 2.78 – 
2.81 (m, 2H),  3.11 (dd J = 7, 3 Hz, 2H), 3.26 (d, J = 7 Hz, 1H), 3.55 (dd, J = 10.7, 2.7 
Hz, 1H), 3.75-3.86 (m, 4H),  4.39 – 4.57 (m, 6H), 5.13 (d, J = 5 Hz, 2H), 5.45 - 5.50 (m, 
1H), 5.61 – 5.70 (m, 1H),  5.56 (d, J = 2.5,  Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1H), 6.76 
(d, J = 8.5 Hz, 2H), 7.02 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 2H),  7.22 (d, J = 8.5 
Hz, 1H), 7.35 (s, 4H), 7.46 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 6.6 Hz, 1H). MS (MALDI, 
DHB) m/z 1219 (M+H, calcd for CR68RHR95RNR7ROR13 Rrequires 1217.70) 
 
 
K-2: To obtain K-2 an additional deprotection step was required to remove the benzyl 
protecting group from isoleucine. K-1, (16.6 mg, 0.0125 mmol) was dissolved in EtOAc 
and MeOH 1:1 ratio (2 ml) and to this was added 15% palladium on charcoal. Hydrogen 
was bubbled through the reaction mixture for 20 mins. The mixture was filtered through 
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celite, concentrated under reduced pressure and dried under high vacuum to yield 16 mg 
of product, white solid. Product from hydrogenolysis (16 mg, 0.013 mmol) was dissolved 
in THF and TBAF in THF (0.039μl) was added. The mixture was stirred at room 
temperature for 20 mins. Column chromatography was performed using CHR2RClR2R: MeOH 
(95:5) initially and then increasing MeOH concentrations to isolate K-2 (14.0 mg, 89%) 
as a yellow solid. MS (MALDI, DHB) m/z 1131 (M+H, calcd for CR61RHR91RNR7ROR13 Rrequires 
1129.67) 
 
 
Figure 3.3: Mass spectrum for K-2 
 
 
3.4 UC-7α PROTACs syntheses /optimization of linker length 
Our initial results from the screening done with the C-16 PROTACs indicated that 
the C-16 PROTAC was not better at degrading the ER than the original E2-penta 
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PROTAC (Figure 3.4). Another observation from Figure 3.4 was that the K-1 PROTAC, 
having the benzyl group was more effective in degrading the ER than K-2 lacking the 
benzyl protection group. Therefore, with the belief that benzyl protection may play a role 
in the activity of the PROTAC, the O-17/E2-penta was re-synthesized to include the 
benzyl protecting group. All four compounds were analyzed for their ability to degrade 
the ER. As displayed in Figure 3.5, the benzyl protected PROTACs showed a greater 
ability to degrade the ER than unprotected PROTACs. However, the O-17 PROTACs 
induced more ER degradation than any of the C-16α PROTACs.  
 
 
 
Figure 3.4 Evaluation of C-16 and O-17 PROTACs on ER degradation.  MCF-7 cells 
were treated with PROTACs at the indicated concentrations (μM) or with DMSO for 
48hrs. Cells were then lysed and analyzed via western blot using anti ERα antibody. β-
actin was used as a loading control. P-OH (E2-penta/O-17 PROTAC), K-1 and K-2 
(benzyl protected and deprotected C-16 PROTACs, respectively). 
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Figure 3.5 Comparisons of C-16α and O-17/E2- Penta PROTACs. MCF-7 cells were 
treated with PROTACs at the indicated concentrations or with DMSO, E2 (10 nM) and 
tamoxifen (TAM 5 μM) for 48hrs. Cells were lysed and analyzed via western blot using 
anti ERα antibody. The intensities of the bands were quantified (%) using volumetric 
densitometry (Quantity One, Bio-Rad). The ERα values were normalized to β-actin and 
DMSO was arbitrarily assigned a value of 100% for comparison purposes. The benzyl 
protected PROTACs were better at degrading the ER than unprotected. K-1 (C-16 
PROTAC- protected C-terminus), K-2 (C-16 PROTAC - unprotected C-terminus), P-bzl 
(E2-penta/O-17 PROTAC- benzyl protected C-terminus), P-OH (E2-penta/O-17 
PROTAC - unprotected C-terminus).  
 
These results indicated that the C-16 position on E2 may not be ideal for the 
development of PROTACs, and as such a more appropriate derivatization site on E2 was 
sought. It has been shown that derivatization at the C-7α position on estradiol results in 
the maintenance of high ER-E2 binding affinity. For example, the ER antagonist 
ICI182,780 which has demonstrated high binding affinity for the ER is a C-7α derivative P 
[185, 186, 187, 188]
P. Based on the above data, the C-7α position on E2 was explored as a 
possible location for further optimization of the PROTAC. The initial assessment of the 
C-16 PROTACs also indicated a possible role for benzyl protection at the C-terminus of 
the penatpeptide; therefore, the C-7 PROTACs contained a benzyl group at the C-
terminus of the pentapeptide as well. 
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USynthesis of C-7 PROTACs handle (free NHUR2R) 
As was the case for the C-16 derivatives the first step in designing C-7α based 
PROTACs was the synthesis of a short primary amine “handle” attached at the C-7α 
position on estradiol which will be further extended to produce PROTACs of varying 
lengths. The procedures that were used to synthesize the C-7α handle were similar to that 
previously reported P [189, 190, 191, 192]P.  
 
Scheme 3.3 Synthesis of C-7 PROTAC’s “handle” (free amine) 
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UReaction details and NMR and MS data for the synthesis of C-7 PROTACs free -amine 
handle 
 
Compound 2: Estradiol, (8.00 g, 29.4 mmol) was dissolved in CHR2RClR2R (100 ml)R Rand p-
toluene sulfonic acid (TsOH), (56 mg, 0.29 mmol) was added, followed by Dihydropyran 
(DHP) (13.3 ml, 146.8 mmol) The mixture was stirred at room temperature, after 2 hours 
water was added and product was extracted with ether. Column chromatography was 
performed to isolate THP protected products as a clear oil (12 g, 94%). 
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.79, 0.81 (2s, 3H), 2.83-2.87 (m, 2H), 3.47-3.52 (m, 
1H), 3.57-3.61 (m, 1H), 3.72 (t, J = 8.5 Hz, 1H), 3.89-3.97 (m, 2H), 4.64 - 4.65 (m, 1H), 
5.38 - 5.39 (m, 1H), 6.78 (d, J = 2.5 Hz, 1H), 6.84 (dd, J = 8.5, 2.5 Hz, 1H), 7.22 (d, J = 8 
Hz, 1H)  
 
Compound 3:  To a -78 °C solution of 2.5 M n-butyl lithium (n-BuLi) in hexanes, (30 
mL, 75.0 mmol) dissolved in THF (50 mL), was added diisopropylamine (10.5 mL, 75.0 
mmol), followed by 1 M potassium t-butoxide (KOt-Bu), (75.0 mL, 75.0 mmol) (a 
yellow color change was observed with addition of KOt-Bu). After 5 min, a solution of 
(2), (4.18 g, 9.49 mmol) dissolved in THF (20 mL) was added resulting in a dark red 
color reaction mixture which was stirred for 1.5 hours  at -78 °C under NR2R. The dry 
ice/acetone bath was replaced with an ice bath and trimethylborate (B(OCHR3R)R3R)  (20 mL, 
171.0 mmol) was slowly added. The reaction was stirred for an additional 2 hours at 0° C 
(reaction became turbid upon adition of (B(OCHR3R)R3R) ).  35%  hydrogen peroxide (HR2ROR2R) 
(25 mL) was then added and the reaction was stirred for 1 hour at room temperature, after 
which time it was cooled to 0 °C, and 10%  sodium thiosulfate (NaR2RSR2ROR3R) (100 mL) was 
added. Product was extracted using EtOAc, dried over NaR2RSOR4R and solvents were 
ecaporated. The crude mixture was dissolved in CHR2RClR2R and flash chromatography was 
performed (3:1, Hex:EtOAc) to afford the 6-OH compound as a pale yellow foam (2.86 
g, 66% ). 
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.79, 0.81 (2s, 3H), 3.45-3.49 (m, 1H), 3.56 - 3.59 (m, 
1H), 3.68 – 3.73 (m, 1H), 3.87-3.93 (m, 2H), 4.63 - 4.67 (m, 1H), 4.78 – 4.81 (m, 1H), 
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5.40 - 5.43 (m, 1H), 6.92 (2dd, J = 8.5, 2.5 Hz, 1H), 7.17, 7.18 (2d, J = 8 Hz, 1H), 7.26 
(d, J = 2.5 Hz, 1H).  
 
Compound 4:  The 6-OH compound, (2.86 g, 6.26 mmol) was dissolved in CHR2RClR2R (30 
mL) and cooled to 0 °C, pyridinium chlorochromate (PCC) (2.7 g, 12.5 mmol) was then 
added in portions within 15 min. After stirring for 15 min at 0 °C, the mixture was 
warmed to room temperature and stirred for an additional 2 hours. The reaction was 
diluted with ether (50 mL) and then filtered through Florisil to remove the chromium 
salts. The solvent was evaporated and the residue was purified via flash chromatography 
(3:1, Hex: EtOAc) to yield (4) as a white foam (2.28 g, 80%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.81, 0.82 (2s, 3H), 2.73 (dd, J =  16.5, 3.5 Hz, 1H), 3.47 
– 3.52 (m, 1H), 3.58 – 3.62 (m, 1H), 3.73, 3.75 (2t, J = 8.5 Hz, 1H), 3.86-3.94 (m, 2H), 
4.63 - 4.69 (m, 1H), 5.46 – 5.48 (m, 1H), 7.21 – 7.26 (2dd, J = 8.5, 3 Hz, 1H), 7.33, 7.34 
(2d, J = 8.5 Hz, 1H), 7.71, 7.72 (2d, J = 3 Hz, 1H).  
 
Compound 5: The  Ketone, (4), (1.91 g, 4.20 mmol) was dissolved in THF and cooled to 
0° C, then 1M KOt-Bu (4.6 ml, 4.60 mmol) was added and mixture was stirred at 0 °C 
for 30 min and then cooled to -78°C. Allyl iodide (383 μL, 4.60 mmol) was then added 
(drop-wise) to the solution and after 10 min the reaction was quenched with water and 
warmed to room temperature. The solvents were removed, redissolved in ether, and then 
passed through a plug of silica (7-β product). After evaporation of solvents, the residue 
(7-β product) was dissolved in MeOH (25 mL), and to this was added several small 
pieces of sodium. The mixture was stirred for an additional 2 hours at room temperature, 
then quenched with water, the MeOH was evaporated, and the product was extracted 
from with ether. The solvents were evaporated and the residue was purified by flash 
chromatography (5:1 Hex:EtOAc) to give (5), the 7-α product as a white foam (272 mg, 
13%), recovered (4) 896 mg, corrected yield 25%. (7-α product- confirmed by NOESY, 
diagonistic NOE between HR7 Rand HR8R). This process was repeated two more times with 
recovered starting material to provide a total (575 mg, overall uncorrected 28%, corrected 
36%).  
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P
1
PH NMR (CDClR3R, 500 MHz): δ 0.80, 0.82 (2s, 3H), 3.47 – 3.52 (m, 1H), 3.60 – 3.62 (m, 
1H), 3.74, 3.77 (2t, J = 8.5 Hz, 1H), 3.87-3.94 (m, 2H), 4.63 - 4.69 (m, 1H), 4.92 – 5.00 
(m, 1H), 5.45 – 5.48 (m, 1H), 5.74 – 5.82 (m, 1H), 7.22 (2dd, J = 8.5, 2.5 Hz, 1H), 7.32, 
7.34 (2d, J = 8.5 Hz, 1H), 7.69 (d, J = 2 Hz, 1H).  
 
Assignment of 7α-sterochemistry to compound (5) by NOESY 2D NMR (scanned image).  
 
 
Compound 6:  Triethylsilane (EtR3RSiH), (4.37 ml) was added to a solution of (5) (205 mg, 
0.41 mmol) in CHR2RClR2R and the mixture was cooled to 0 °C. Boron trifluoride 
diethyletherate (BFR3R.EtR2RO) (15 ml) was added (drop-wise) and the mixture was warmed 
H7
NOE7-8
H8
NOE7-8
6
H7
H8
O
O
O
THP
THP
H9
compound (5) 
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to room temp and stirred overnight (greenish-yellow color change). Reaction mixture was 
then carefully hydrolyzed with 10% KR2RCOR3R (72 ml) and filtered through a buccner 
funnel. The filtrate was extracted with CHR2RClR2R, dried over NaR2RSOR4R and flash 
chromatography was performed (1:1, Hex:EtOAc) to yield a white solid (116 mg, 90%). 
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.79 (s, 3H), 2.72 (d, J = 16 Hz, 1H), 2.83 (dd, J = 17, 
5.5 Hz, 1H), 3.77 (t, J = 8.5 Hz, 1H), 4.91 - 5.00 (m, 1H), 5.74 – 5.82 (m, 1H), 6.54 (d, J 
= 3 Hz, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H). 
 
Compound 7:  Imidazole, (303 mg, 4.45 mmol) was dissolved in CHR2RClR2 Rand DMF (10 
ml and 2 mL respectively) and was cooled to 0 °C for about ten mins.  TBDMSCl (335 
mg, 2.23 mmol) was then added and the mixture was warmed to room temperature. A 
solution of (6), (116 mg, 0.37 mmol in 3 ml DMF) was added to the mixture and stirred 
overnight at room temeprature. CHR2RClR2 Rand DMF was evaporated and 0.1% KR2RCOR3R (30 
mL) was added. The crude product was extracted with CHR2RClR2R and passed through a 
short column (3:1 Hex:EtOAc)  to yield (7) as a yellow oil (170 mg, 85%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.18 (s, 6 H), 0.75 (s, 3H), 0.89 
(s, 9H), 0.97 (s, 9H), 2.70 (d, J = 16 Hz, 1H), 2.83 (dd, J = 17, 5.5 Hz, 1H), 3.65 (t, J = 
8.5 Hz, 1H), 4.88 – 4.98 (m, 1H), 5.74 – 5.82 (m, 1H), 6.52 (d, J = 2.5 Hz, 1H), 6.61 (dd, 
J = 8.5, 2.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H). 
 
Compound 8: A 0.5 M solution of 9-boro-bicyclononane (9-BBN) in THF (3.14 mL, 
1.57 mmol) was added to a solution of steroid (7) (170 mg, 0.31 mmol) already dissolved 
in THF (10 mL). After stirring overnight at room temperature the reaction was cooled to 
0 °C and quenched with 3 M potassium hydroxide (KOH), (2 mL), after 5 min 35% 
HR2ROR2R (2 mL) was added and the reaction was stirred for an addidional 3 h. Saturated 
NaHCO3 was added and the mixture was extracted with CHR2RClR2R. The residue was 
purified by flash chromatography (5:1 Hex:EtOAc) to provide (8) as a viscous oil (116 
mg, 66%).  
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.19 (s, 6 H), 0.74 (s, 3H), 0.89 
(s, 9H), 0.97 (s, 9H), 2.68 (d, J = 16 Hz, 1H), 2.88 (dd, J = 16.7, 5.5 Hz, 1H), 3.58 – 3.60 
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(m, 2H), 3.65 (t, J = 8.5 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.61 (dd, J = 8.5, 2.5 Hz, 1H), 
7.11 (d, J = 8.5 Hz, 1H). 
 
Compound 9:   To a cooled solution (0 °C) of triphenyl phosphine (PPh3) (97 mg, 0.415 
mmol) and THF (5 mL), was added Diisopropyl azo-dicarboxylate (DIAD) (dropwise) 
(77 μl, 0.415 mmol). A white precipitate of the ylide was observed, and the reaction was 
stirred for 40 min at 0 °C. A solution of (8), (116 mg, 0.207 mmol) and phthalimide (58 
mg, 0.415 mmol) in THF (2 mL) was then added to the ylide. The reaction was stirred for 
1 h at 0 °C and then at room temperature overnight. The solvent was evaporated in vacuo, 
and the residue was purified via flash chromatography (5:1 Hex:EtOAc) to give (9) as a 
white foam (118 mg, 83%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.18 (s, 6 H), 0.74 (s, 3H), 0.89 
(s, 9H), 0.99 (s, 9H), 2.67 (d, J = 16.5 Hz, 1H), 2.87 (dd, J = 17, 5 Hz, 1H), 3.55 – 3.68 
(m, 3H), 6.52 (d, J = 2.5 Hz, 1H), 6.60 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 
7.69 – 7.72 (m, 2H), 7.81 – 7.83 (m, 2H). 
 
Compound 10: Anhydrous hydrazine (800 μl) was added to a solution of (9), (118 mg, 
0.171 mmol) dissolved in DME (1.6 mL) and ethanol (1.6 mL). The mixture was refluxed 
for 2 h, during which time a slightly brown precipitate formed on the sides of the flask 
and the solution turned slightly green. The reaction was cooled, and 5% NaOH (1.6 mL) 
was added, dissolving the precipitate. After 30 min, water was added, and the solution 
was extracted with CHR2RClR2R, dried over NaR2RSOR4R. The solvent was evaporated in vacuo, 
and the residue was purified via flash chromatography (95:5, CHR2RClR2R: MeOH) to give 10 
as a white foam solid (56.7 mg, 76%). The TBDMS group at the 3-OH position is lost 
during this reaction. 
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H),  0.74 (s, 3H), 0.89 (s, 9H), 2.68 
(d, J = 16.5 Hz, 1H), 2.88 (dd, J = 17, 5 Hz, 1H), 3.65 (t, J = 8.5 Hz, 1H), 6.50 (d, J = 2.5 
Hz, 1H), 6.59 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H) 
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UOptimization of linker length of C-7 PROTACs 
 Successful synthesis of the free amine handle at the C-7α position allowed us to 
vary the linker length via amide bond formation. To this end, we prepared PROTACs 
with varying linker lengths. In addition, two other PROTACs, one lacking the critical 
hydroxyl-proline residue (NC) and another attached at the C-terminal of the HIF-1α 
derived pentapeptide (KC-6), were prepared. The schemes and detailed reaction 
conditions for the synthesis of C-7 PROTACs are outlined below:  
 
Scheme 3.4  Synthesis of KC-1 (9-atom linker) 
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USynthesis of KC-1  
 
Compound 11: Disuccinimidyl gluterate DSG (54 mg, 0.166 mmol) was added to the 
free amine “handle”, (10), (37 mg, 0.083 mmol) and dissolved in DMF (2 ml). The 
mixture was stirred at room temp overnight. DMF was removed via high vacuum and 
column chromatography was performed (95:5, CHR2RClR2R: MeOH) to give the product as a 
white solid (25 mg, 46%). For this reaction two products were isolated having similar 
mobility on TLC. The upper product which was later identified by NMR to be the correct 
product was reactive while the other product was unreactive in subsequent reactions.  
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.52 
(t, J = 7 Hz, 2H), 2.63 (d, J = 16.5 Hz, 1H), 2.83 (s, 4H), 3.18 – 3.26 (m, 2H), 3.65 (t, J = 
8.5 Hz, 1H), 5.92 (t, J = 5.5 Hz, 1H),  6.50 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz, 
1H), 7.11 (d, J = 8.5 Hz, 1H). 
 
Compound 12: Pentapeptide-1 (24 mg, 0.009 mmol) was added to (11), (34 mg, 0.009 
mmol) and then dissolved in DMF (1.5 ml). The reaction was stirred at room temp 
overnight. Solvent was removed in vacuo and column chromatography was performed 
(95:5 CHR2RClR2R: MeOH) to yield (12) as a white solid (34 mg, 70%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.77 – 0.85 (m, 
6H), 0.87 – 0.94 (m, 6H), 0.89 (s, 9H), 1.30 (s, 9H), 2.63 (d, J = 16 Hz, 1H), 2.77 (s, 1H), 
2.83 (dd, J = 17, 4.5 Hz, 1H), 2.93 – 3.10 (m, 3H), 3.57 (m, 1H), 3.64 (t, J = 8.5 Hz, 1H), 
3.75 (d, J = 11 Hz, 1H), 4.36 – 4.67 (m, 6H), 5.11 (s, 2H),  6.53 (d, J = 2.5 Hz, 1H), 6.62 
(dd, J = 8.5, 2.5 Hz, 1H), 6.74 (t, J = 5.5 Hz, 1H), 6.84 (d, J = 8 Hz, 2H), 7.04 (d, J = 8.5 
Hz, 2H), 7.09 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 7.5 Hz, 1H), 7.28 – 7.33 (m, 4H), 7.55 (d, 
J = 7.5 Hz, 1H), 7.59 (d, J = 7 Hz, 1H). 
 
KC-1: t-Butyl from Tyr-OH and TBDMS protecting group at the O-17 position was 
simultaneously removed from (12), (34 mg, 0.027 mmol) using neat TFA (2 ml)R Rand 
stirring at room temperature until starting material disappeared ~30 min. After removal of 
TFA via high vacuum, column chromatography was performed using (95:5, CHR2RClR2R: 
MeOH) initially, then MeOH to isolate KC-1 as a white solid (13.8 mg, 47%). 
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P
1
PH NMR (CDClR3R, 500 MHz): δ  0.75 (s, 3H), 0.82 – 0.96 (m, 12H), 2.63 (d, J = 17 Hz, 
1H), 3.19 (m, 1H), 3.49 (m, 1H), 3.57 (m, 1H), 3.68 (t, J = 8.5 Hz, 1H), 4.32 – 4.38 (m, 
2H), 4.49 – 4.55 (m, 4H),  5.12 (s, 2H), 6.53 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 
Hz, 1H), 6.72 (d, J = 8.5 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 1H), 7.28 
(d, J = 8 Hz, 1H), 7.31 – 7.34 (m, 4H), 7.51 (d, J = 7 Hz, 1H), 7.71 (2d, J = 7 Hz, 2H). 
MS (MALDI, DHB) m/z 1130 (M+Na P+P, calcd for CR62RHR86RNR6ROR12 Rrequires 1129.63) 
 
Figure 3.6: Mass spectrum for KC-1 
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Scheme 3.5 Synthesis of KC-2 (12 atom linker) 
 
 
 
USynthesis of KC-2 
 
Compound 13: Disuccinimidyl suberate (DSS), (12 mg, 0.033 mmol), was added to free 
amine “handle”, (10), (14.6 mg, 0.033 mmol) and dissolved then dissolved in DMF 
(1ml). The mixture was stirred at room temp overnight. DMF was removed via high 
vacuum and column was performed (95:5 CHR2RClR2R: MeOH) to give a white solid (5.7 mg, 
25%). For this reaction two products were isolated having similar mobility on TLC. The 
49 
 
upper product which was later identified by NMR to be the correct product was reactive 
while the other isomer was unreactive in subsequent reactions.  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.12 
(t, J = 7.5 Hz, 2H), 2.58 (t, J = 7.5 Hz, 2H), 2.65 (d, J = 16.5 Hz, 1H), 2.82 – 2.87 (m, 
5H), 3.08 – 3.12 (m, 1H), 3.24 – 3.29 (m, 1H), 3.65 (t, J = 8.5 Hz, 1H), 5.76 (t, J = 5.5 
Hz, 1H),  6.53 (d, J = 2.5 Hz, 1H), 6.61 (s, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J 
= 8.5 Hz, 1H). 
 
Compound 14: Pentapeptide-1, (6 mg, 0.008 mmol) was added to (13), (5.7 mg, 0.008 
mmol) and dissolved in DMF (1.5 ml). The reaction was stirred at room temp overnight. 
Solvent was removed in vacuo and column chromatography was performed using (95:5 
CHR2RClR2R: MeOH) to yield (14) as a white solid (6.6 mg, 66%)  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.79 – 0.85 (m, 
6H), 0.87 – 0.95 (m, 6H), 0.89 (s, 9H), 1.13 – 1.33 (m, 13H), 1.31 (s, 9H), 2.63 (d, J = 
16.5 Hz, 1H), 2.83 (dd, J = 16.5, 4.5 Hz, 1H), 2.97 – 3.10 (m, 3H), 3.23 – 3.27 (m, 1H), 
3.56 (dd, J = 11.1, 3.9 Hz, 1H), 3.64 (t, J = 8.5 Hz, 1H), 3.75 (d, J = 11 Hz, 1H), 4.47 – 
4.62 (m, 6H), 5.11 (2s, 2H),  6.53 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz, 1H), 6.66 
(d, J = 8 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 
1H), 7.30 – 7.37 (m, 4H), 7.51 (d, J = 7 Hz, 1H). 
 
KC-2: Trifluoroacetic acid (TFA) was used to remove both protecting groups (TBDMS 
and t-Bu).  Neat TFA was added to (14), (6.6 mg, 0.005 mmol), and the mixture was 
stirred at room temperature until starting material disappeared, (45 min) observed on 
TLC.  Column chromatography was performed using (95:5, CHR2RClR2R: MeOH) initially, 
then column was flushed with MeOH to isolate KC-2 as a white solid (2.5 mg, 42%).   
P
1
PH NMR (CDClR3R, 300 MHz): δ  0.74 (s, 3H), 0.79 – 0.85 (m, 6H), 0.87 – 0.95 (m, 6H), 
2.63 (d, J = 16.5 Hz, 1H), 2.83 (dd, J = 16.5, 4.5 Hz, 1H), 2.97 – 3.10 (m, 3H), 3.23 – 
3.27 (m, 1H), 3.53 (dd, J = 11.1, 3.9 Hz, 1H), 3.64 (t, J = 8.5 Hz, 1H), 3.75 (d, J = 11 Hz, 
1H), 4.36 – 4.54 (m, 6H), 5.14 (s , 2H),  6.53 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 
Hz, 1H), 6.74 (d, J = 8 Hz, 1H), 7.02 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 1H), 7.25 
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(d, J = 8 Hz, 1H), 7.38 (s, 4H), 7.48 (d, J = 7.5 Hz, 1H), 7.54 (d, J = 7 Hz, 1H). MS 
(MALDI, DHB) m/z 1172 (M+NaP+P, calcd for CR65RHR92RNR6ROR12 Rrequires 1171.68) 
 
Figure 3.7: Mass spectrum for KC-2 
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Scheme 3.6 Synthesis of KC-3 (16 atom linker) 
 
 
 
 
USynthesis of KC-3 
Compound 15: Fmoc-6-aminohexanoic acid (6-Ahx-OH/caproic acid) (13.4 mg, 0.038 
mmol) was added to free amine “handle” (10), (17 mg, 0.038 mmol) and dissolved in 
CHR2RClR2R. HBTU (21.6 mg, 0.057 mmol) and HoBt (8.73 mg, 0.057 mmol) was added to 
the mixture followed by DIPEA (2 drops) The mixture was stirred at room temp until all 
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free amine was coupled (15 min-1.5 hr). Column chromatography was performed (99:1 
CHR2RClR2R: MeOH) yielding a white foamy solid (27 mg, 91%). A small amount of di-
coupled product was isolated as well (5%). In some coupling reactions EDC was used as 
a coupling agent instead of HBTU providing cleaner reaction (only mono-coupled) 
product, but lower yields. 
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.62 
(d, J = 16.5 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.04 – 3.10 (m, 1H), 3.14 (q, J = 6.5 
Hz, 2H), 3.29 – 3.34 (m, 1H), 3.64 (t, J = 8.3 Hz, 1H), 4.21 (t, J = 7 Hz, 1H), 4.41 (d, J = 
7 Hz, 2H), 4.97 (t, J = 6 Hz, 1H), 5.47 (t, J = 6 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H),  6.62 
(dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 7.30 – 7.33 (td, J = 7.5, 1.2 Hz, 2H), 
7.40 (t, J = 7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H). 
 
Compound 16: Fmoc-group from (15) was removed using 20% piperidine in DMF (2 
ml) for 10 minutes. Following removal of solvents in vacuo, flash column 
chromatography was performed using (CHR2RClR2R: MeOH 95:5) initially to remove by 
products and finally flushing with MeOH to isolate (16) as white solid (14 mg, 73%).  
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.89 (s, 9H), 2.60 
(d, J = 16.5 Hz, 1H), 2.87 (dd, J = 16.5, 4.7 Hz 1H), 3.36 – 3.48 (m, 4H), 3.65 (t, J = 8 
Hz, 1H), 5.50 (t, J = 5.4 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H),  6.62 (dd, J = 8.5, 2.5 Hz, 1H), 
7.11 (d, J = 8.5 Hz, 1H). 
 
Compound 17: DSG (16.4 mg, 0.050 mmol) was added to (16), (14 mg, 0.025 mmol) 
and dissolved in DMF (1.5 ml). The mixture was stirred at room temp for 15 min. DMF 
was removed via high vacuum and column chromatography was performed using (99:1 
CHR2RClR2R: MeOH) to remove excess DSG and then (95:5 CHR2RClR2R: MeOH) to give (17) as 
a white solid (7 mg, 37%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.89 (s, 9H), 2.60 
(d, J = 16.5 Hz, 1H), 2.31 (t, J = 7 Hz, 2H), 2.67 (t, J = 7 Hz, 2H), 2.87 ( s, 4H), 3.00 – 
3.05 (m, 1H), 3.18 – 3.24 (m, 2H), 3.31 – 3.35 (m, 1H),  3.65 (t, J = 8 Hz, 1H), 5.69 (t, J 
= 5.5 Hz, 1H), 6.39 (t, J = 5.5 Hz, 1H), 6.56 (d, J = 2.5 Hz, 1H),  6.64 (dd, J = 8.5, 2.5 
Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H). 
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Compound 18: Pentapeptide-1 (10 mg, 0.013 mmol) was added to (17) (7 mg, 0.009 
mmol) with catalytic amount of DMAP and then dissolved in DMF (1.5 ml). The reaction 
was stirred at room temp overnight. Solvent was removed in vacuo and column 
chromatography was performed (95:5 CHR2RClR2R: MeOH) to yield (18) as a white solid (9 
mg, 74%)  
P
1
PH NMR (DMSO, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.69 (s, 3H), 0.79 - 0.86 (m, 
12H), 0.87 (s, 9H), 1.25 (s, 9H), 2.58 (d, J = 16.5 Hz, 1H), 3.66 (t, J = 8 Hz, 1H), 4.22 – 
4.33 (m, 4H), 4.42 (t, J = 6.7 Hz, 1H), 4.47 – 4.51 (m, 1H), 5.11 (s, 2H),  6.42 (d, J = 2.5 
Hz, 1H), 6.51 (dd, J = 8.5, 2.5 Hz, 1H), 6.82 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 1H), 
7.11 (d, J = 8.5 Hz, 2H), 7.36 – 7.37 (m, 4H), 7.71 (t, J = 5.5 Hz, 1H), 7.74 (t,  J = 5.5 
Hz, 1H), 7.82 (d, J = 8 Hz, 1H), 7.92 (d, J = 8 Hz, 1H), 8.03 (t, J = 7 Hz, 1H). 
 
KC-3: (18), (9 mg, 0.005 mmol) was dissolved in THF (0.5 ml) and TBAF in THF (0.5 
ml) was added to remove TBDMS protecting group from O-17 position. Mixture was 
stirred at room temperature until starting material disappeared (48 hrs). Column 
chromatography was performed using (CHR2RClR2R: MeOH 95:5) initially, then column was 
flushed with MeOH to isolate KC-3 as a white solid (2.8 mg, 34%). In subsequent 
reactions the OH on tyrosine was protected and TFA was used to remove both protecting 
groups (TBDMS and t-Bu).   
P
1
PH NMR (DMSO, 500 MHz): δ 0.65 (s, 3H), 0.79 - 0.86 (m, 13H), 2.56 (d, J = 16.5 Hz, 
1H), 2.75 (dd, J = 16.5, 4.5 Hz, 1H), 3.50 – 3.54 (m, 2H), 4.20 – 4.24 (m, 2H), 4.28 – 
4.33 (m, 2H), 4.40 – 4.43 (m, 2H), 4.50 – 4.51 (m, 1H), 5.10 (s, 2H),  6.41 (d, J = 2.5 Hz, 
1H), 6.49 (dd, J = 8.5, 2.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8 Hz, 2H), 7.04 
(d, J = 8.5 Hz, 1H), 7.36 (s, 4H), 7.71 (t, J = 5.5 Hz, 1H), 7.74 (t,  J = 5.5 Hz, 1H), 7.77 
(d, J = 8.5 Hz, 1H), 7.91 (d, J = 8 Hz, 1H), 8.00 (d, J = 8 Hz, 1H), 8.02 (d, J = 7 Hz, 1H). 
MS (MALDI, CHCA) m/z 1243 (M+Na P+P, calcd for CR68RHR97RNR7ROR13 Rrequires 1242.71) 
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Figure 3.8: Mass spectrum for KC-3 
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Scheme 3.7 Synthesis of KC-4 (19 atom linker) 
 
 
 
USynthesis of KC-4 
 
Compound 19: Fmoc-6-aminohexanoic acid (6-Ahx-OH/caproic acid) (37 mg, 0.104 
mmol) was added to the free amine “handle” (10), (46 mg, 0.104 mmol) and then 
dissolved in CHR2RClR2R. EDC, (28 mg, 0.156 mmol) was added to the mixture followed by 
DIPEA (2 drops). The mixture was stirred at room temp until all the free amine was 
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coupled (15 min-1.5 hr) monitored by TLC. Column chromatography was performed 
using (99:1, CHR2RClR2R: MeOH) to yield a white foamy solid (61 mg, 75%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.62 
(d, J = 16.5 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.04 – 3.10 (m, 1H), 3.14 (q, J = 6.5 
Hz, 2H), 3.29 – 3.34 (m, 1H), 3.64 (t, J = 8.3 Hz, 1H), 4.21 (t, J = 7 Hz, 1H), 4.41 (d, J = 
7 Hz, 2H), 4.97 (t, J = 6 Hz, 1H), 5.47 (t, J = 6 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H),  6.62 
(dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 7.30 – 7.33 (td, J = 7.5, 1.2 Hz, 2H), 
7.40 (t, J = 7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H). 
 
Compound 20: Fmoc from (19) was deprotected using 20% piperidine in DMF (3.5 ml) 
for 15 minutes at room temp. Following removal of solvents in vacuo flash column 
chromatography was performed using (95:5, CHR2RClR2R: MeOH) initially to remove by-
products and finally flushing with MeOH to isolate (20) as a white solid (39.5 mg, 91%).  
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.89 (s, 9H), 2.60 
(d, J = 16.5 Hz, 1H), 2.87 (dd, J = 16.5, 4.7 Hz 1H), 3.36 – 3.48 (m, 4H), 3.65 (t, J = 8 
Hz, 1H), 5.50 (t, J = 5.4 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H),  6.62 (dd, J = 8.5, 2.5 Hz, 1H), 
7.11 (d, J = 8.5 Hz, 1H). 
 
Compound 21: DSS (52 mg, 0.142 mmol) was added to (20) (39.5 mg, 0.071 mmol) and 
dissolved in DMF (1.5 ml). The mixture was stirred at room temp overnight. DMF was 
removed via high vacuum and column was performed (99:1 CHR2RClR2R: MeOH) to give (21) 
as a white solid (17.6 mg, 31%). Coupling confirmed by negative Kaiser test. 
 
Compound 22: Pentapeptide-1 (16 mg, 0.022 mmol) was added to (21), (17.6 mg, 0.022 
mmol) with catalytic amount of DMAP and dissolved in CHR2RClR2R (1.5 ml). The reaction 
was stirred at room temp overnight. Solvent was removed under reduced pressure and 
column chromatography was performed (95:5, CHR2RClR2R: MeOH) to yield (22) as a white 
solid (19 mg, 61%)  
P
1
PH NMR (500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.80 - 0.95 (m, 12H), 
0.89 (s, 9H), 1.31 (s, 9H), 2.63 (d, J = 16.8 Hz, 1H), 2.85 (dd, J = 16.8, 4.2, 1H), 3.06 (d, 
J = 7.2 Hz, 3H), 3.13 – 3.27 (m, 4H), 3.55 (dd, J = 11.1, 3.6 Hz, 1H), 3.65 (t, J = 8 Hz, 
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1H), 4.40 – 4.43 (m, 2H), 4.48 – 4.56 (m, 4H), 4.47 – 4.51 (m, 1H), 5.12, (s, 2H),  6.35 (t, 
J = 5.7 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 6.63 (dd, J = 8.4, 2.4 Hz, 2H), 6.68 (t, J = 5.8 
Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 5 Hz, 1H), 6.95 (d,  J = 5.7 Hz, 1H), 7.09 
(d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.34 (s, 4H). 
 
KC-4: TBDMS and t-Bu protecting groups were removed simultaneously by adding neat 
TFA (1ml) to (22), (19 mg, 0.013 mmol) and stirring at room temperature until all 
starting material disappeared (30 mim). TFA was removed in vacuo and column 
chromatography was performed using (95:5 CHR2RClR2R: MeOH) to isolate KC-4 as a white 
solid (3.6 mg, 22%). MS (MALDI, SA) m/z 1262.8 (M+H, calcd for CR71RHR103RNR7ROR13 
Rrequires 1261.76) 
 
Figure 3.9: Mass spectrum for KC-4 
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Scheme 3.8 Synthesis of KC-5 (21 atom linker) 
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USynthesis of KC-5 
 
Compound 23: Fmoc-caprylic acid (18 mg, 0.047 mmol) was added to the free amine 
“handle” (10), (21 mg, 0.047 mmol) already dissolved in CHR2RClR2R. EDC (13.5 mg, 0.070 
mmol) was added to the mixture followed by DIPEA (2 drops) and mixture was stirred at 
room temp until all free amine was coupled (15 min-1.5 hr) monitored by TLC. Column 
chromatography was performed, (99:1, CHR2RClR2R: MeOH) yielding a white foamy solid (32 
mg, 84%).  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.60 
(d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.04 – 3.10 (m, 1H), 3.12 (q, J = 7.4 
Hz, 2H), 3.64 (t, J = 8.3 Hz, 1H), 4.17 (t, J = 7 Hz, 1H), 4.34 (d, J = 7 Hz, 2H), 5.00 (t, J 
= 6 Hz, 1H), 5.82 (t, J = 6 Hz, 1H), 6.51 (d, J = 2.5 Hz, 1H),  6.62 (dd, J = 8.5, 2.5 Hz, 
1H), 7.06 (d, J = 8.5 Hz, 1H), 7.30 – 7.31 (td, J = 7.5, 1.0 Hz, 2H), 7.39 (t, J = 7.5 Hz, 
2H), 7.56 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7.5 Hz, 2H). 
 
Compound 24: Fmoc group from (23), (32 mg, 0.040 mmol) was removed using 20% 
piperidine in DMF (2ml) for 10 minutes at room temperature. Following removal of 
solvents in vacuo flash column chromatography was performed using (CHR2RClR2R: MeOH 
95:5) initially to remove by-products and finally flushing with MeOH to isolate (24) as 
white solid (13 mg, 56%). Deprotection confirmed by Kaiser test. 
 
Compound 25: DSS (42 mg, 0.111 mmol) was added to (24) (13 mg, 0.022 mmol) and 
the reagents were dissolved in DMF (2.5 ml) the mixture was stirred at room temp 
overnight. DMF was removed via high vacuum and column was performed (99:1 
CHR2RClR2R: MeOH) to give (25) as a white solid (5.8 mg, 31%).  
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.60 
(t, J = 7.2 Hz, 1H), 2.84 (s, 2H), 3.21 – 3.28 (m, 2H),  3.64 (t, J = 8.3 Hz, 1H),  5.61(t, J = 
5.7 Hz, 1H), 5.87 (t, J = 5.7 Hz, 1H), 6.55 (d, J = 2.5 Hz, 1H),  6.66 (dd, J = 8.5, 2.5 Hz, 
1H), 7.11 (d, J = 8.5 Hz, 1H). 
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Compound 26: Pentapeptide-1 (5.2 mg, 0.007 mmol) was added to (25), (5.8 mg, 0.007 
mmol) with catalytic amount of DMAP and dissolved in CHR2RClR2R (3 ml). The reaction 
was stirred at room temp overnight. Solvent was removed under reduced pressure and 
column chromatography was performed (95:5 CHR2RClR2R: MeOH) to yield (26) as a white 
solid (4.8 mg, 48%)  
P
1
PH NMR (500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.80 - 0.95 (m, 12H), 
0.89 (s, 9H), 1.31 (s, 9H), 2.63 (d, J = 16.8 Hz, 1H), 2.85 (dd, J = 16.8, 4.2, 1H), 3.06 (d, 
J = 7.2 Hz, 3H), 3.13 – 3.27 (m, 4H), 3.55 (dd, J = 11.1, 3.6 Hz, 1H), 3.65 (t, J = 8 Hz, 
1H), 4.40 – 4.43 (m, 2H), 4.48 – 4.56 (m, 4H), 4.47 – 4.51 (m, 1H), 5.13 (s, 2H),  6.35 (t, 
J = 5.7 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 6.63 (dd, J = 8.4, 2.4 Hz, 2H), 6.68 (t, J = 5.8 
Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 5 Hz, 1H), 6.95 (d,  J = 5.7 Hz, 1H), 7.09 
(d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.34 (s, 4H). 
 
KC-5: TBDMS and t-Bu protecting groups were removed simultaneously by adding neat 
TFA (1ml) to 26 (4.8 mg, 0.003 mmol) and stirring at room temperature until all starting 
material disappeared (30 mim). TFA was removed in vacuo and column chromatography 
was performed (CHR2RClR2R: MeOH 95:5) to isolate KC-5 as a white solid (0.8 mg, 19%). 
MS (MALDI, SA) m/z 1312 (M+NaP+P, calcd for CR73RHR107RNR7ROR13 Rrequires 1312.79) 
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Figure 3.10: Mass spectrum for KC-5 
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Scheme 3.9 Synthesis of KC-6 ( 12 atom linker attached at the C-terminus of HIF-
pentapeptide) 
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USynthesis of KC-6  
 
Compound 27: Fmoc-caprylic acid (29.2 mg, 0.077 mmol) was added to the free amine 
“handle” (10), (34 mg, 0.077 mmol) and then dissolved in CHR2RClR2R. EDC (22 mg, 0.115 
mmol) was added to the mixture followed by DIPEA (2 drops) and mixture was stirred at 
room temp until all free amine was coupled (15 min-1.5 hr), monitored by TLC. Column 
chromatography was performed (99:1, CHR2RClR2R: MeOH) yielding a white foamy solid (53 
mg, 62%).  
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.62 
(d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.06 – 3.30 (m, 4H), 3.64 (t, J = 8.3 
Hz, 1H), 4.20 (t, J = 7 Hz, 1H), 4.40 (d, J = 7 Hz, 2H), 4.91 (t, J = 5.5 Hz, 1H), 5.54 (t, J 
= 5.5 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H),  6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.5 
Hz, 1H), 7.32 (m, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.75 (d, J = 7.5 
Hz, 2H). 
 
Compound 28: Fmoc from (27), (53 mg, 0.065 mmol) was deprotected using 20% 
piperidine in DMF (3 ml) for 10 minutes at room temperature. Following removal of the 
solvents in vacuo, flash column chromatography was performed using (95:5 CHR2RClR2R: 
MeOH) initially to remove by-products and finally flushing with MeOH to isolate (28) as 
white solid (30 mg, 79%).  
 
Compound 29: Pentapeptide-3 (17 mg, 0.023 mmol) was added to (28) (13.6 mg, 0.023 
mmol) and both were dissolved in DMF (1.5 ml). The reaction was stirred at room temp 
overnight. Solvent was removed in vacuo and column chromatography was performed 
(4:1 CHR2RClR2R: MeOH) to yield (29) as a white solid (17 mg, 56 %). 
P
1
PH NMR (CDClR3R, 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.62 
(d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.00 – 3.26 (m, 5H), 3.64 (t, J = 8.3 
Hz, 1H), 4.20 – 4.25 (m, 2H), 4.22 – 4.56 (m, 3H), 5.10 (s, 2H), 6.53 (d, J = 2.5 Hz, 1H),   
6.63 (dd, J = 8.5, 2.5 Hz, 1H), 6.74 (t, J = 8 Hz, 2H), 6.94 (d, J = 8 Hz, 1H), 7.00 (d, J = 8 
Hz, 2H), 7.11 (d, J = 8 Hz, 1H), 7.22 (d, J = 8 Hz, 1H), 7.31(m, 2H), 7.89 (d, J = 6 Hz, 
1H). 
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KC-6: TBDMS protecting group was removed by adding neat TFA (1ml) to (29) (9.8 
mg, 0.007 mmol) and stirring at room temperature for 30 mim. TFA was removed in 
vacuo and column chromatography was performed (CHR2RClR2R: MeOH 95:5) to isolate KC-
6 as a white solid (6 mg, 67%).  
P
1
PH NMR (CDClR3R, 300 MHz):  0.77 (s, 3H),  2.64 (d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 
4.7 Hz 1H), 3.04 – 3.20 (m, 4H), 3.67 (t, J = 8.3 Hz, 1H), 4.20 – 4.23 (m, 2H), 4.37 – 
4.56 (m, 3H), 5.10 (s, 2H), 5.90 (d, J = 8 Hz, 1H), 5.96 (d, J = 8.5 Hz, 1H),  6.16 (d, J = 6 
Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 6.73 (t, J = 8.5 Hz, 2H), 
6.92 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 8.5 Hz, 2H), 7.27 – 7.32 
(m, 2H), 7.56 (d, J = 6 Hz, 1H), 7.79 (d, J = 7 Hz, 1H). MS (MALDI, CHCA) m/z 1200.7 
(M+NaP+P, calcd for CR66RHR95RNR7ROR12 Rrequires 1200.7) 
 
 
Figure 3.11: Mass spectrum for KC-6 
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Scheme 3.10 Synthesis of NC – (negative control, HyP substituted with norleucine)  
 
 
USynthesis of NC – negative control 
 
Compound 30: DSS, (108 mg, 0.394 mmol) was added to the free amine “handle” (10), 
(35 mg, 0.079 mmol) and both were dissolved in DMF (5 ml). The mixture was stirred at 
room temp overnight. DMF was removed via high vacuum and column chromatography 
was performed (95:5, CHR2RClR2R: MeOH) to give a white solid (17 mg, 31%).  
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P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.73 (s, 3H), 0.89 (s, 9H), 2.12 
(t, J = 7.5 Hz, 2H), 2.58 (t, J = 7.5 Hz, 2H), 2.65 (d, J = 16.5 Hz, 1H), 2.82 – 2.87 (m, 
5H), 3.08 – 3.12 (m, 1H), 3.24 – 3.29 (m, 1H), 3.65 (t, J = 8.5 Hz, 1H), 5.76 (t, J = 5.5 
Hz, 1H),  6.53 (d, J = 2.5 Hz, 1H), 6.61 (s, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J 
= 8.5 Hz, 1H). 
 
Compound 31: Pentapeptide-2, (8.5 mg, 0.011 mmol) was added to (30), (8 mg, 0.011 
mmol) and both were dissolved in CHR2RClR2R (1.5 ml). The reaction was stirred at room 
temp overnight. Solvent was removed under reduced pressure and column 
chromatography was performed (95:5 CHR2RClR2R: MeOH) to yield (31) as a white solid (9.3 
mg, 62%)  
P
1
PH NMR (CDClR3R, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H),  0.74 (s, 3H), 0.81 – 0.95 (m, 
12H), 0.89 (s, 9H), 1.30 (s, 9H), 2.65 (d, J = 16.5 Hz, 1H), 2.86 (dd, J = 16.5, 4.8 Hz, 
1H), 2.92 (d, J = 6 Hz, 1H), 2.06 – 3.13 (m, 2H), 3.20 – 3.30 (m, 1H), 3.70 – 3.46 (m, 
5H), 3.66 (t, J = 8.5 Hz, 1H),  4.21 – 4.36 (m, 3H), 4.47 -4.50 (m, 1H), 4.57 – 4.64 (m, 
1H), 5.13 (s , 2H),  6.47 (d, J = 4.5 Hz, 1H), 6.22 (d, J = 8.5 Hz, 1H), 6.50 (dd, J = 8.5, 
2.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 1H), 
7.22 (d, J = 7.5 Hz, 1H),  7.26 (d, J = 8.5 Hz, 1H), 7.35 (s, 4H), 7.44 (d, J = 7.5 Hz, 1H), 
7.57 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 6 Hz, 1H). 
 
NC: TBDMS and t-Bu protecting groups were removed simultaneously by adding neat 
TFA (1ml) to (31) (9.3 mg, 0.007 mmol) and stirring at room temperature for 30 min. 
TFA was removed in vacuo and column chromatography was performed (95:5, CHR2RClR2R: 
MeOH) to isolate NC as a white solid (2.9 mg, 36%).  
MS (MALDI, SA) m/z 1149.8 (M+H, calcd for CR65RHR92RNR6ROR12 Rrequires 1149.68) 
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Figure 3.12: Mass spectrum for NC 
 
 
 
3.5 Synthesis of KC-7/Dimeric ligand PROTAC 
 
 Based on the fact that a number of proteins exist as dimers, (including the ER, 
which dimerizes upon E2 binding) attempts have been made to produce dimeric 
compounds that can interact with both members of such dimersP [193, 194, 195]P. It is thought 
that dimeric ligands that are suitably engineered, having a proper spacer between the two 
ligands, for example, should produce higher selectivity and potency when compared to 
their monomeric counterpartsP [194]P.  
As such the synthesis of dimeric ligands as: anti-cancer agents, example, 
geldanamycin dimer targeting Hsp90 and HER2  P [196]P ; anti-HIV agents example disulfide 
benzamides (DIBAs) dimers,  that were found to selectively target the HIV-
1nucleocapsid protein zinc (NCp7 Zn) fingersP [197]P. Dimeric ER lignads have also been 
M+H
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synthesized from both steroidal and non steroidal ligandsP [195, 198, 199, 200]P. Hexestrol dimers 
showed some antiestrogenic activitiesP [198]P and a triphenylethylene dimer containing six 
hydroxyls had similar activity to tamoxifen, but was not specific for ER positive breast 
cancer cellsP [201]P. Estrone dimers were also synthesized but, had no antiestrogenic activity 
and in fact stimulated cell proliferation similar to E2P [200]P. Other ER dimers were linked at 
the 17-β position on E2 and showed minimal cytotoxicity in MCF-7 cells when compared 
with tamoxifen, but were cytotoxic to murine skin cancer cellsP [195, 199]P.  
Similar to the aforementioned studies, in an attempt to improve the efficiency of 
the PROTAC, a dimeric PROTAC was synthesized. The dimeric PROTAC was linked at 
the C-7α position on E2 (unlike the other ER targeting dimers previously mentioned 
aboved), which we hope would retain the binding affinity for the ER. The Scheme and 
reaction details for synthesis of the dimeric PROTAC are reported below. 
 
 
. 
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Scheme 3.11 Synthesis of KC-7/dimeric ligand PROTAC 
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Scheme 3.11 Synthesis of KC-7/dimer continued 
 
 
UReaction details for synthesis of KC-7/dimeric ligand PROTAC 
 
Compound 2: The 3-OH deprotected compound isolated from the synthesis of (8) in 
scheme 3, was re-protected with a benzyl group. KR2RCOR3R (1.2 g, 8.50 mmol) was added to 
(8) (470 mg, 1.06 mmol) and contents were dissolved in DMF, benzyl bromide (BnBr) 
(195 μl, 1.60 mmol) was then added and the reaction was stirred overnight at room 
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temperature. DMF was removed in vacuo and column chromatography was performed 
(5:1 Hex:EtOAc) to yield (2) (454 mg, 80%).  
P
1
PH NMR (CDCl3, 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.74 (s, 3H), 0.89 (s, 9H), 2.73 
(d, J = 16.5 Hz, 1H), 2.92 (dd, J = 17, 5 Hz, 1H), 3.60 (t, J = 6.2 Hz, 2H), 3.65 (t, J = 8 
Hz, 1H), 5.02 (s, 2H), 6.70 (d, J = 2.5 Hz, 1H), 6.78 (dd, J = 8.7, 2.7 Hz, 1H), 7.20 (d, J = 
8.5 Hz, 1H), 7.30- 7.44 (m, 5H) 
  
Compound 3: To a cooled solution (0 °C) of PPh3 (443 mg, 1.70 mmol) in THF (10 mL) 
was added DIAD (dropwise) (332 μl, 1.70 mmol). A white precipitate of the ylide was 
observed, and the reaction was stirred for 40 min at 0 °C. A solution of (2), (454 mg, 
0.850 mmol) and phthalimide (249 mg, 1.70 mmol) dissolved in THF (5 mL) was then 
added to the ylide. The reaction was stirred for 1 h at 0 °C and then at room temperature 
overnight. The solvent was evaporated under reduced pressure and the residue was 
purified via flash chromatography (5:1 Hex:EtOAc) to give (3) as a white foam (369 mg, 
65%).  
P
1
PH NMR (CDCl3, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.72 
(d, J = 17 Hz, 1H), 2.92 (dd, J = 17, 5 Hz, 1H), 3.60 (t, J = 6.2 Hz, 2H), 3.65 (t, J = 8 Hz, 
1H), 5.01 (s, 2H), 6.70 (d, J = 2.5 Hz, 1H), 6.76 (dd, J = 8.7, 2.7 Hz, 1H), 7.20 (d, J = 8.5 
Hz, 1H), 7.30- 7.44 (m, 5H), 7.69- 7.71 (m, 2H), 7.82- 7.83 (m, 2H) 
 
Compound 4: Three different deprotection reactions were performed to give (4).  (i) 
deprotection of TBDMS:  hydrogen fluoride (HF) (540 μl) was added to a 25 ml round 
bottom flask containing (3), (172 mg, 0.260 mmol), already dissolved in THF and 
CHR3RCN. The mixture was heated to approximately 60°C for 20 min. After cooling, the 
mixture was quenched with saturated NaHCOR3R and then solid NaHCOR3 Runtil neutral, then 
extracted with CHR2RClR2R. After drying over NaR2RSOR4R the solvent was evaporated under 
reduced pressure and the residue was purified via flash chromatography (5:1 Hex:EtOAc)  
(134 mg).  (ii) release of free amine:  Product (134 mg, 0.244 mmol) obtained from (i) 
above was dissolved in equal amounts of DME and EtOH (5 ml and 5 ml) and hydrazine 
(163 μl) was added and the mixture was refluxed for 2 h, during which time slightly 
brown precipitate formed on the sides and the solution turned slightly green. The reaction 
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was cooled, and 5% NaOH was added, dissolving the precipitate. After 30 min, water 
was added, and the solution was extracted with CHR2RClR2R, dried over NaR2RSOR4R and the 
solvent was evaporated in vacuo. The residue was purified via flash chromatography 
(95:5, CHR2RClR2R: MeOH) to give the amine as a white foam solid (79 mg). (iii) 
hydrogenolysis: The amine from (ii) (79 mg) was dissolved in 1:1 EtOAc: MeOH and 
10% palladium on charcoal (Pd-C) (12 mg) was added, hydrogen was bubbled through 
the mixture and the reaction was monitored by TLC until all starting material 
disappeared. Mixture was filtered through celite and solvent was evaporated to yield (4) 
as a white solid (58 mg, 96%).  
P
1
PH NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H), 2.67 (d, J = 17 Hz, 1H), 2.88 (dd, J = 17, 5 
Hz, 1H), 3.70 (t, J = 8 Hz, 1H),  6.54 (d, J = 2.3 Hz, 1H), 6.63 (dd, J = 8.5, 2.3 Hz, 1H), 
7.11 (d, J = 8.5 Hz, 1H) 
 
 
Compound 5:  Fmoc-caprylic acid (28.6 mg, 0.075 mmol) was added to (4), (24.7 mg, 
0.075 mmol) dissolved in CHR2RClR2 Rand DMF. HBTU (43 mg, 0.112 mmol) and was added 
to the mixture followed by DIPEA (2 drops) and mixture was stirred at room temp for 30 
min. solvents were removed in vaccuo and the residue was purified by column 
chromatography (CHR2RClR2R: MeOH 95:5) yielding a white foamy solid (17.5 mg, 34%). 
Fmoc from the product above (ii) (17.5 mg, 0.075 mmol) was deprotected using 20% 
piperidine in DMF. After solvent removal the residue was purified via flash column 
chromatography (CHR2RClR2R: MeOH 95:5) to yield (5), (11 mg, 92%).  Amine was 
confirmed using Kaiser test. 
 
Compound 6:  Pentapeptide-3 (18 mg, 0.023 mmol) and DMAP was added to (5) (11 
mg, 0.023 mmol) and the contents were dissolved in DMF (2.5 ml). The reaction was 
stirred at room temp overnight. The solvents were removed in vacuo and column 
chromatography was performed (4:1 CHR2RClR2R: MeOH) to yield (6) as a white solid (17 
mg, 63 %)  
P
1
PH NMR (CDCl3, 500 MHz): δ 0.66 (s, 3H), 0.67 – 0.87 (m, 16H), 2.57 (d, J = 16.5 Hz, 
1H), 2.72 – 2.80 (m, 2H), 2.94 – 2.99 (m, 4H), 3.45 – 3.57 (m, 3H), 4.04 – 4.23 (m, 2H), 
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4.28 – 4.49 (m, 4H), 4.51 (d, J = 5 Hz, 1H), ( )5.02 (s, 2H), 6.41 (d, J = 2.5 Hz, 1H), 6.50 
(dd, J = 8.5, 2.5 Hz, 1H), 6.60 – 6.63 (m, 2H), 6.97 – 7.01 (m, 2H), 7.05 (d, J = 8.5 Hz, 
1H), 7.29 - 7.46 (m, 5H), 7.65 (d, J = 9.5 Hz, 1H), 7.82- 7.83 (m, 2H), 7.86 (d, J = 8 Hz, 
1H), 8.00 (d, J = 7 Hz, 1H), 8.06 (d, J = 7 Hz, 1H),  8.19 (d, J = 6 Hz, 1H) 
 
Compound 7: (6), (17 mg, 0.015 mmol) was dissolved in 1:1 EtOAc: MeOH, Pd-C was 
added and hydrogen was bubbled through the mixture for 1hr. The mixture was filtered 
through celite and solvent evaporated to give (7) as a pale yellow solid (15 mg, 98%). 
Free amine confirmed by Kaiser test. 
 
Compound 8: DSS (15 mg, 0.042 mmol) was added to (7) (15 mg, 0.014 mmol) and 
dissolved in DMF (0.5 ml) the mixture was stirred at room temp overnight. DMF was 
removed via high vacuum and column chromatography was performed (95:5 CHR2RClR2R: 
MeOH) to give (8) as a yellow solid (5.5 mg, 31%).  
P
1
PH NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H), 0.80 – 1.01 (m, 10 H), 1.02 (t, J = 6.5 Hz, 
3H), 2.30 (t, J = 7.5 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 3.02 – 3.24 (m, 5H), 3.47 – 3.54 
(m, 1H), 3.63 – 3.72 (m, 3H), 4.17 – 4.27 (m, 1H), 4.43 – 4.54 (m, 4H), 6.36 (t, J = 6 Hz, 
1H),  6.40 (t, J = 6 Hz, 1H),  6.53 (d, J = 2.5 Hz, 1H), 6.63 (dd, J = 8.5, 2.5 Hz, 1H), 6.75 
(t, J = 8.5 Hz, 2H), 6.95 (d, J = 8 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 8.5Hz, 
1H), 7.14 (d, J = 4.5 Hz, 1H), 7.16(d, J = 4.5 Hz, 1H), 7.26 (d, J = 7Hz, 1H), 7.58 (t, J = 
6 Hz, 1H), 7.73 (t, J = 6 Hz, 1H),  
 
Compound 9: (8), (5.5 mg, 0.004 mmol), (4) (3 mg, 0.009 mmol) and DMAP was 
dissolved in DMF and mixture was stirred at room temperature overnight. Solvents were 
removed in vaccuo and flash column chromatography was performed (95:5 CHR2RClR2R: 
MeOH) to give the (KC7/dimer) as a yellow solid (4.1 mg, 68%). Mass spectrum 
indicated below. MS (MALDI, SA) m/z 1534 (M+Na P+P, calcd for CR87RHR130RNR8ROR14 Rrequires 
1533.97) 
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Figure 3.13: Mass spectrum for Dimer 
 
 
3.6 Summary  
 
Syntheses resulted in the development of ten PROTACs. Two C-16α PROTACs, 
K1 and K2 were synthesized (Scheme 3.2) having a linker attached at the C-16α position 
via a carbon-carbon (C-C) bond. The C-C bond was used as an alternative to the ester 
bond used in the original ER-targeting PROTAC (Figure 3.1). The C-terminal benzyl 
protecting group on the HIF derived pentapeptide was not removed in K-1 in order to 
evaluate its potential in stabilizing the PROTAC while the benzyl group was removed 
from K-2 analogous to the O-17/E2-penta PROTAC. 
All other PROTACs were synthesized as C-7α PROTACs. In this series eight 
PROTACs were developed. Five were developed in an attempt to optimize the linker 
length, KC-1, KC-2, KC-3, KC4, and KC-5, (Scheme 3.4 to 3.8). In an effort to decipher 
whether the location of attachment of the linker to the HIF pentapeptide was important, a 
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PROTAC KC6 (Scheme 3.9) was also synthesized having the linker attached at the C-
terminal isoleucine residue. To help validate the mechanism of PROTAC action the 
critical Hyp was replaced with a nor-leucine reside. A dimeric PROTAC was also 
developed in the hope of improving the PROTAC efficiency.  
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CHAPTER 4: BIOLOGICAL CHARACTERIZATIONS 
 
The data presented in this chapter were generated in collaboration with Marie 
Wehenkel (western blot, immunofluorescence, rt-PCR), Hyeong- Jun Han (MTS assay), 
Dr. Eun-Young Choi (binding assay) and, Dr. Wooin Lee’s lab - Eun Young Jang & 
Kyungwha Kim (qrt-PCR). Thanks to the following laboratories for use of their 
equipment: Dr. Tai (microplate reader), Dr. Dr. Wooin Lee (fluorescence microscope) 
and Drs. Black, Graf, and Leggas (fluorescence microscope). 
 
 
4.1 Introduction 
 
PROTACs were tested in MCF-7 breast cancer cells for their ability to ER induce 
degradation. MCF-7 cells were treated with PROTACs and the effect of PROTACs on 
ERα protein levels was evaluated using western blot and immunofluorescence (IF). ICR50 
Rwas also established for all compounds. Once an optimum compound was identified it 
was screened further for its potential effects on the ER downstream target gene, the 
progesterone receptor (PR). The belief is that if ER is degraded then genes that are 
normally dependent on ER for transcriptional activation will display only basal 
expression levels. 
 
 
4.2 Materials and Methods 
 
 UReagents: 
The following reagents were obtained from Bio-Rad: Tris-Cl Triton X-100, 
Protein Assay Dye Reagent Concentrate, Sodium Dodecyl Sulfate (SDS) 20% (w/v), 
0.5M Tris-HCl Buffer pH 6.8, 1.5M Tris-HCl Buffer pH 8.8, 30% Acrylamide/Bis 
Solution 29:1, Immun-Blot PVDF Membrane, Blocking Grade Non-Fat Dry Milk, and 
Prestained SDS-PAGE Standards, Low Range. 
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The following reagents were obtained from Sigma-Aldrich: Protease Inhibitor 
Cocktail; Sample Buffer, Laemmli 2X Concentrate; Ammonium Persulfate (APS); 
N,N,N',N'-Tetramethylethylenediamine (TEMED); Bovine Serum, Albumin (BSA); 
Kodak GBX Developer/Replenisher; Kodak GBX Fixer/Replenisher; Kodak BioMax 
XAR Film;Sodium Bicarbonate; Glycero; HEPES; Magnesium Chloride (MgClR2R) 
hexahydrate, 99%, ACS reagent; TWEEN® 20; Ethylenediaminetetraacetic acid 
(EDTA); Phosphatase Inhibitor Cocktail 1; Dithiothreitol (DTT); and Sodium 
Orthovanadate (NaR3RVOR4R). 
The following reagents were obtained from Gibco: Goat Serum; Fetal Bovine 
Serum (FBS) heat inactivated; 10X Hanks’ Balanced Salt Solution (HBSS); Penicillin-
Streptomycin (P/S); RPMI Medium 1640; 10X Trypsin-EDTA (TE); and RPMI 1640 
Medium phenol-red free. 
Additional reagents were supplied by other companies.  The Amersham ECL 
Western Blotting Detection Reagents were purchased from GE Healthcare, Sodium 
Chloride and Methylsulfoxide (DMSO) were purchased from EMD, Nonidet-P40 was 
purchased from Fluka, PVDF membranes were purchased from Biorad, Prolong Gold 
antifade w/ DAPI was purchased from Invitrogen, CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay was purchased from Promega, Charcoal/Dextran Treated Fetal 
Bovine Serum was purchased from Hyclone, Antibody Dilutant w/ Background Reducing 
Components was purchased from DAKO, Potassium Chloride (KCl) ACS Grade  was 
purchased from EM Science, Formaldehyde, Para (PFA), Laboratory Grade was 
purchased from Fisher Scientific, Potassium Phosphate Monobasic (KHR2RPOR4R) and 
Sodium Phosphate Dibasic Heptahydrate (NaR2RHPOR4R) were both purchased from 
Mallinckrodt Baker. β-glycerolphosphate was a kind gift from Dr. Penni Black. 
 
UAntibodies: 
The following primary antibodies were used for western blotting: Estrogen 
Receptor-α (ERα), Histone deacetylase 1 (HDAC1), (Santa Cruz).  Cyclin D1, 
(NeoMarkers) and β-actin (Novus Biologicals).   
Secondary antibodies: Anti-Mouse IgG horseradish peroxidase (Host: Goat) 
(Zymed); Anti-Rabbit IgG horseradish peroxidase (Host: Donkey),  (Amersham).  
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Antibodies for immunofluorescence:  Primary antibody, ERα (Abcam).   
Conjugated secondary antibody Alexa Fluor 488 (FITC) goat anti-rabbit IgG   
(Invitrogen).  Also from Invitrogen was the f-actin stain Rhodamin Phallodin, which was 
first dissolved in methanol according to the manufacturer’s instructions and then used at a 
concentration of 1:1000 in PBS [R415]. 
 
 
UCell Culture & Treatment: 
MCF7 cells were purchased from the American Type Culture Collection 
(Manassas, VA) and maintained in RPMI 1640 Medium supplemented with 10% (v/v) 
fetal bovine serum and a mixture of 100U/mL penicillin and 100µg/mL streptomycin 
(P/S).  Cells were grown in an incubator at 37°C with a 5% carbon dioxide atmosphere.  
Media was changed to RMPI plus P/S with 5% Charcoal/Dextran-treated FBS after 
washing with HBSS and at least 24 hours prior to treatment of the cells with compounds.  
Cells were added to 12 or 24 well plates and treated once they reached 70% confluence.  
Compounds were treated in a DMSO vehicle at the appropriate dilutions for 48 hours, 
unless noted otherwise.   
 
UWestern Blotting:  
Whole cell lysates were prepared by incubating cells in nondenaturing lysis buffer 
(50nM Tris-Cl, 150mM NaCl, 1% NP40, 1% Triton X-100, and 1% protease inhibitor 
cocktail) on ice for 1 hour. Cells were then centrifuged at 14,000 rpm for 10 min at 4°C 
(Sorvall Biofuge Primo R, Kendro Laboratory Products, Newtown, CT). Supernatants 
were collected and subjected to protein assay via method of Bradford using Protein Assay 
Dye Reagent Concentrate. Protein concentrations were determined by a GENESYS 10 
spectrophotometer, Thermo Spectronic (VWR, Arlington Heights, IL). The supernatants 
were then added 2x Laemmli Sample Buffer and heated in boiling water for 10 min. 
Subsequently, the denatured whole cell lysates were resolved by 8%-12% SDS-PAGE 
and transferred to PVDF membranes. Membranes were blocked with 5% skim milk or 
BSA for 1 hour at room temperature on the rotator. Appropriate primary and secondary 
antibodies were used to incubate the membranes for 1 hour at room temperature on the 
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rotator or overnight at 4°C. Finally, Amersham ECL Western Blotting Detection 
Reagents were used to visualize protein of interests on Kodak BioMax XAR Films. 
Antibodies were used at the following dilutions: ERα (1:200), β-actin (1:5000), anti-
rabbit (1:10000 or 1:5000), and anti-mouse (1:5000).  Exposure: ERα (1-5 minutes), and 
β-actin (5-60 seconds).     
 
 
UQuantification: 
The intensities of the bands on western blot films were quantified using 
volumetric densitometry (Quantity One, Bio-Rad).  The estrogen receptor-alpha values 
were normalized to β-actin and DMSO was arbitrarily assigned a value of 100% for 
comparison purposes. 
 
UCell Proliferation Assay: 
Cells were seeded in a 96 well plate at a concentration of 5,000 cells per well and 
allowed to attach for 24 hours.  The media was changed to 5% Charcoal RPMI for 24 
hours prior to the addition of compounds.  During the 48 hour treatment, ten 
concentrations were tested plus one vehicle and one media control.  At the end of the 
treatment time, 20µL of the CellTiter 96® assay dye was added to the media in each well 
and allowed to react at 37°C for one hour.  Absorbance was then measured at 490nm on a 
microplate reader using the KC4 data analysis program from BioTek®.  In GraphPad 
Prism® (San Diego, USA), ICR50R values were obtained from a sigmoid dose-response 
curve using a nonlinear regression to a logarithmic function.  The data represent at least 
three replicates. 
 
UImmunofluorescence: 
 Coverslips were sterilized with ethanol and UV light exposure in 35mm dishes.  
Cells were added directly to the dish and allowed to attach for 24 hours.  The media was 
then changed to phenol-red free RPMI with 5% Charcoal/Dextran-treated FBS until 
treatment with compounds.  Compounds were diluted in the phenol-red free media, and 
treated as detailed previously. 
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After treatment, cells were fixed with 4% PFA at 37°C for 7 minutes, washed 
with PBS, and then permeablized with 0.2% Triton-X in PBS at 37°C for 30 minutes.  
Between all subsequent steps coverslips were washed in PBST (PBS with 0.05% Tween-
20).  Blocking in 10% goat serum with 0.1% BSA in PBST was performed at 37°C for 1 
hour or 4°C overnight.  Primary antibody (ERα) was added directly to the coverslip at a 
concentration of 1:1000 in DAKO antibody dilutant at 37°C for one hour, then secondary 
antibody (FITC) was added in the same way for 30 minutes.  The f-actin stain was diluted 
to 1:1000 in PBS, added directly to the coverslip, and incubated at 37°C for 30 minutes.  
After extra washing, the coverslips were removed from the dishes and dried briefly.  
20µL of Prolong Gold with DAPI per coverslip was added to clean slides and the 
mounted slides were allowed to dry overnight.  After drying, the coverslips were rimmed 
with clear nail polish and visualized on a fluorescent microscope. 
 
UCompetitive Ligand Binding AssayU: 
Competitive ligand binding assays were performed according to the 
manufacturer’s protocol (Invitrogen). Purified human recombinant estrogen receptor 
(approximately 10 nM) was added to a saturating amount of [P3 PH]-labeled estradiol (20 
nM) and the indicated concentrations of E2 or PROTACs. After incubating for 2 hr at 
room temperature or overnight at 4Po PC, a 50% hydroxy apatite slurry was added to bind 
the receptor/ligand complex and the sample was centrifuged. The resuspended pellet was 
then analyzed for tritium activity using scintillation counting and the percent specific 
binding affinity was calculated.  ICR50R values were obtained using one site competition 
equation (Y = Bottom + (Top-Bottom) / 1 + 10PX-LogEC50 P) provided by the Graph Pad 
Prism® software.  Relative binding affinity (RBA) was calculated using the following 
equation, RBA = [ICR50R (E2)/ICR50R (sample)] X 100.  
 
UqRT-PCR: 
MCF-7 cells were seeded in 6 well plates at a density of 250,000 cells per well 
and given 24 hours to attach.  The media was changed to 5% Charcoal RPMI for 24 hours 
prior to the addition of compounds.  Wells (four per condition) were treated with the 
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indicated concentrations of compounds for 48 hours. Cells were collected by 
trypsinization and stored at -80°C until lysis. 
RNA was extracted from the cell pellets using the TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions.  RNA concentration was determined using 
NanoDrop (Thermo Scientific).  One microgram of total RNA was employed to create 
cDNA utilizing the iScript™ cDNA synthesis kit (Bio-Rad) according to the 
manufacturer’s instructions.  Reaction conditions: 25µL total volume, 5 minutes at 25°C, 
30 minutes at 42°C, 5 minutes at 85°C, followed by a hold at 4°C.  The cDNA was stored 
at -20°C until qrt-PCR was performed. 
The real time reactions (run in triplicate) were performed using an iCycler (Bio-
Rad) with the iQ SYBR Green Supermix (Bio-Rad), 200nM of the forward/reverse 
primers, and 2µL of cDNA.  The following gene-specific primers reported previouslyP [202]P 
were used: PR (fwd): 5’-ATCAGGCTGTCATTATGGTGT-3’; PR (rev): 5’-
AAATTTTCGACCTCCAAGGAC-3’; β-actin (fwd): 5’-
GCATCCTCACCCTGAAGTAC-3’; β-actin (rev): 5’-
GATAGCACAGCCTGGATAGC-3’.  The reactions for PR were carried out with 
annealing at 60℃ for 40 cycles while the reactions for β-actin were carried out with 
annealing at 65℃ for 40 cycles.  A melting curve analysis was included in each real time 
reaction to ensure the specificity of the amplified products.  Average cycle threshold (Ct) 
values for PR was calculated and normalized to Ct values for β-actin, using the ∆∆Ct 
method as an internal control, with the fold-change plotted in GraphPad Prism® and the 
product of four independent replicates. 
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4.3 UResults 
 
Initial western blot screening assessed the effects of C-16α PROTACs vs. O-
17/E2-penta PROTAC (the first generation PROTAC). The result showed (Figure 3.4) 
that the C-16α PROTAC was not better at degrading the ER than the original PROTAC; 
however, K-1, which has a C-terminal benzyl protecting group, showed better activity 
against the ER when compared to K-2, which is not protected (Scheme 3.2 for 
structures). Further evaluation using the C- terminus protected O-17/E2-penta PROTAC 
(Figure 3.5), indicated a possible role for benzyl protection at the C-terminus of the 
pentapeptide in enhancing PROTAC activity. Based on the data from these western blot 
studies it was decided that the C-16α position was not ideal for linker attachment and 
further length optimization of the PROTAC. As such, addditional PROTACs with the 
linker attached at the C-7α position on E2 and a benzyl protecting group at the C-
terminus of the pentapeptide was synthesized. 
 
UAnalysis of C-7 PROTACs 
 
C-7 vs C-16 PROTACs: 
The C-7α position was chosen for further optimization based on the reported 
success of compounds derivatized at that position P [178, 203, 204, 205]P. Length optimization 
was performed at the C-7α position (chapter 3). The different PROTACs were analyzed 
for their ability to degrade the ER in a dose dependent manner. ER levels were evaluated 
by western blot (Figure 4.1). The C-7α PROTAC containing the DSS extender, (KC-2), 
was compared to the C-16α PROTACs, which also has the DSS extender. As observed in 
Figure 4.1, K-1 and KC-2 showed similar ability to degrade the ER in a dose dependent 
manner, while K-2 did not show a dose dependent increase in ER degradation, again 
highlighting a possible role for benzyl protection, as both K-1 and KC-2 contain the 
benzyl protecting group.  
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Figure 4.1 Dose dependent degradation of ERα by C-16α and C-7α PROTACs: K-1, 
K-2 and KC-2 respectively. MCF-7 cells were treated with PROTACs at the indicated 
concentrations or with DMSO for 48hrs. Cells were lysed and analyzed via western blot 
using anti ERα antibody. The intensities of the bands were quantified (%) using 
volumetric densitometry (Quantity One, Bio-Rad). The ERα values were normalized to β-
actin and DMSO was arbitrarily assigned a value of 100% for comparison purposes. K-1 
(C-16 PROTAC- protected C-terminus), K-2 (C-16 PROTAC - unprotected C-terminus), 
KC-2 (C-7 PROTAC –benzyl protected C-terminus).  
 
 
C-7α PROTACs bind to ERα with higher affinity than C-16α PROTACs: 
 An efficient PROTAC should be able to maintain relatively good binding for the 
ER; therefore, competitive binding assays were employed to establish the affinities of the 
PROTACs for the ER.  Comparison of the binding affinities of selected C-7α PROTACs 
with C-16α PROTACs demonstrates that the C-7α PROTACs bind the ER with a 
significantly higher affinity than the C-16α PROTACs (Figure 4.2). The dimeric 
PROTAC and its monomeric counterparts KC-2 and KC-6 bind to ER with the best 
affinity followed by the KC-3 PROTAC. The lower ER-binding affinity of C-16 
PROTACs may explain the low ER degradation induced by the C-16 PROTACs. Based 
on this data and the data from Figure 3.4, it was concluded that a C-16α based PROTAC 
will not be a useful PROTAC strategy.   
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Figure 4.2 Relative binding affinities of C-7α PROTACs and C-16α PROTACs. 
Competitive ligand binding assays were performed as described in "Materials and 
Methods" using purified ERα .  The ordinate is Bx/Bo, specifically bound radioligand in 
the presence of a given amount of competitor (Bx) divided by specifically bound 
radioligand in the absence of competitor.  The values represent the mean ± SE and are 
represented as percent of that obtained using [ P3 PH]-17β estradiol alone.  
 
Comparison of linker lengths 9, 12 and 16 atoms (KC-1, KC-2 and KC-3 respectively):  
The linker between the two moieties of the PROTAC has not been optimized; 
therefore, to establish the optimal linker length required for PROTAC activity, five 
PROTACs with varying linker lengths were developed (chapter 3). The short linker 
PROTACs within the series, KC-1 and KC-2 was compared to KC-3, the mid-length 
PROTAC for their ability to degrade the ER in MCF-7 cells. As evidenced in Figure 4.3 
western blot data indicated that all PROTACs were capable of degrading the ER at the 
concentrations tested. 
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Figure 4.3 Analyses of C-7α PROTACs KC-1, KC-2 and KC-3 on ER degradation. 
MCF-7 cells were treated with PROTACs at the indicated concentrations or with DMSO 
or TAM (5 μM) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα 
antibody. The intensities of the bands were quantified (%) using volumetric densitometry 
(Quantity One, Bio-Rad). The ERα values were normalized to β-actin and DMSO was 
arbitrarily assigned a value of 100% for comparison purposes. *data are not typical of 
KC-2 at that concentration. 
 
 
 
Comparison of linker lengths 16, 19 and 21 atoms (KC-3, KC-4 and KC-5 respectively)  
 We next wanted to determine the maximum linker length required for PROTAC 
activity. Accordingly, the activity of the two longest linker PROTACs, KC-4 and KC-5, 
were evaluated along with KC-3 for their ability to degrade the ER. Western blot analysis 
indicates a higher level of ER degradation, in a dose dependent manner, in the presence 
of KC-3 while KC-4 and KC-5 had very little effect on inducing ER degradation1T, ( 1TFigure 
4.4). This suggests that the linkers between the two moieties in KC-4 and KC-5 may be 
too long to allow for effective ubiquitin transfer to the ER and as such is unable to recruit 
the ER to the proteasome for degradation. 
 
 
 
 
 
 
 
* 
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Figure 4.4 ER degradation by KC-3, KC-4 and KC-5. MCF-7 cells were treated with 
PROTACs at the indicated concentrations or with DMSO or TAM (5 μM) for 48hrs. 
Cells were lysed and analyzed via western blot using anti ERα antibody. The intensities 
of the bands were quantified (%) using volumetric densitometry (Quantity One, Bio-
Rad). The ERα values were normalized to β-actin and DMSO was arbitrarily assigned a 
value of 1 for comparison purposes.  
 
Effects of low PROTAC dose on the degradation of ER:  
 Based on the fact that KC-1, KC-2 and KC-3 showed an ability to induce ER 
degradation (Figure 4.3); we wanted to investigate the ability of all the PROTACs to 
degrade ER at a low dose to determine which was more potent. All PROTACs, with the 
exception of KC-3, caused a significant accumulation of the ER that was comparable to 
the levels induced by tamoxifen. KC-3 had no significant effect on ER accumulation at 
low concentrations (Figure 4.5), suggesting again a possible role for linker length in 
PROTAC activity, where KC-3 could represent an optimal spacer between the two 
moieties.  
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Figure 4.5: Effect on ER degradation at low doses of PROTACs. MCF-7 cells were 
treated with PROTACs at the indicated concentrations or with DMSO or TAM (5 μM) 
for 48hrs. Cells were lysed and analyzed via western blot using anti ERα antibody. The 
intensities of the bands were quantified (%) using volumetric densitometry (Quantity 
One, Bio-Rad). The ERα values were normalized to β-actin and DMSO was arbitrarily 
assigned a value of 100% for comparison purposes. 
 
Proteasome dependent ER degradation induced by PROTAC: 
 An appropriately designed PROTAC will require the ubiquitin proteasome 
pathway for its action. The proposed mechanism of action of PROTACs, as discussed in 
Chapter 2, is that upon binding of the PROTAC to the ER the HIF-1α derived 
pentapeptide will be recognized by the pVHL, and the ER-PROTAC complex will be 
ubiquitinated and ultimately degraded by the proteasome. In order to examine the 
proteasome dependence of the PROTAC, a specific proteasome inhibitor, epoxomicin 
(epx), was used (Figures 4.6 and 4.7). The results showed that epoxomicin significantly 
inhibited ER degradation at a concentration of 100 nM, indicating that ER degradation by 
the PROTACs is proteasome-dependent. 
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Figure 4.6 Proteasome dependent degradation of ER by PROTACs.  MCF-7 cells 
were co-treated with increasing concentrations (10, 50, 100 nM) of the proteasome 
inhibitor epoxomicin and PROTACs (25 μM) or E2 (100 nM) or TAM (5 μM, positive 
control) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα 
antibody. The intensities of the bands were quantified (%) using volumetric densitometry 
(Quantity One, Bio-Rad). The ERα values were normalized to β-actin and DMSO was 
arbitrarily assigned a value of 100% for comparison purposes.  
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Figure 4.7 Determination of ER degradation via immunofluorescence following 
treatment with DMSO, KC-3 PROTAC and proteasome inhibitor epoxomicin 
(Epx). MCF-7 cells were treated with DMSO or KC-3 or KC-3 and Epx for 48 hrs. Cells 
were then fixed on glass slides and treated with ERα monoclonal antibody, DAPI and 
secondary antibody FITC. Green (estrogen receptor-FITC), blue (DAPI nuclear stain) 
 
Protac is dependent on E3 ubiquitin ligase: 
 It is not sufficient to show proteasome dependence as the ER itself is targeted for 
degradation by the UPS. In that case, degradation of ER is tied to E2-ER induced 
transcriptional activation of target genes P [206, 207]P. The ability of the PROTACs to be 
specifically recognized by the pVHL E3 ligase complex is key for the action of 
PROTACs. In that respect a negative control PROTAC, NC, was synthesized lacking the 
critical hydroxyl proline required for pVHL E3 ubiquitin ligase recognition. Evaluation 
DMSO 
25μM KC-3 
25μM KC-3 + 100 nM Epx 
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of NC and KC-2, that both contain the same linker length suggests that the pVHL is 
required for the PROTAC-induced ER degradation (Figure 4.8), as KC-2, which has the 
proline residue, was better at inducing ER degradation, than NC. 
 
 
Figure 4.8 Evaluation of the pVHL dependence for PROTAC activity. MCF-7 cells 
were treated with PROTACs at the indicated concentrations or with DMSO, E2 (10 nM), 
or TAM (5 μM) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα 
antibody. NC (negative control PROTAC) 
 
C- vs. N-terminus pentapeptide coupling 
 Coupling of the pentapeptide to the linker is through the N-terminal Leu residue 
while the C-terminal Ile is protected with a benzyl group. To investigate whether the site 
for coupling of the linker to the pentapeptide is important for PROTAC activity, an 
alternative PROTAC, KC-6, which has an N-terminal Z group and is coupled to the 
linker via the C-terminal Ile was developed. KC-2, which has the same linker as KC-6, 
but is connected to the linker via the N terminal Leu residue, was compared with KC-6. 
Western blot analysis showed that KC-2 was more effective at causing degradation of the 
ER, indicating a possible role for peptide orientation in PROTAC activity (Figure 4.9).  
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Figure 4.9 N- terminus (KC-2) coupling vs C- terminus (KC-6). MCF-7 cells were 
treated with increasing concentrations of PROTACs DMSO or TAM (5 μM) for 48hrs. 
Cells were lysed and analyzed via western blot using anti ERα antibody. The intensities 
of the bands were quantified (%) using volumetric densitometry (Quantity One, Bio-
Rad). The ERα values were normalized to β-actin and DMSO was arbitrarily assigned a 
value of 100%.  
 
 
KC-3 inhibits MCF-7 cell proliferation with an ICR50 Rsimilar to that of tamoxifen 
 An optimum PROTAC will have the ability to block the proliferation of MCF-7 
cells which express high levels of ER. A cell viability assay (MTS) as described in 
materials and methods was used to test the effects of PROTACs on MCF-7 cell 
proliferation. The dose response curves (Figure 4.10) and the ICR50R for the various 
PROTACs are summarized in Table 4.1. Although a number of PROTACs were capable 
of degrading the ER, an investigation of the ICR50 Rvalues indicated that the KC-3 
PROTAC was most effective in blocking proliferation of MCF-7 cells, displaying values 
comparable to tamoxifen (Table 4.1). This data combined with the degradation data, 
suggested that the KC-3 PROTAC may the optimal length PROTAC among the 
monomeric PROTACs.  
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Figure 4.10 Dose response curves from MTS cell proliferation assay. Following the 
treatment of MCF-7 cells with PROTACs or Tamoxifen for 48 hrs, MTS assay was 
performed as stated in “Materials and Methods”. The ICR50 Rvalues (Table 4.1) were 
obtained In GraphPad Prism® (San Diego, USA), from a sigmoid dose-response curve 
using a nonlinear regression to a logarithmic function.  Data represent at least three 
replicates. 
 
Table 4.1 ICR50 Rvalues of PROTACs  
Compound Dosage ICR50R (μM) 
Error
95% CI 
Tamoxifen 0.50μM to 50µM 27.43 ± 2.59
KC-1 1µM to 200µM 139.3 ± 49.85
KC-2 1µM to 200µM 94.82 ± 18.66
KC-3 1µM to 200µM 25.68 ± 5.83
KC-4 1µM to 200µM > 200 ---
KC-5 1µM to 200µM > 200 ---
KC-6 1µM to 200µM 162.9 ± 90.23
NC 1µM to 200µM > 200 ---
Dimer 1µM to 200µM > 200 ---
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KC-3 does not induce ER-regulated progesterone receptor (PR) to the same extent as 
E2. 
To assess the capability of the optimal length PROTAC to influence ER regulated 
transcriptional activity, the PR, a known downstream target of the ER, was analyzed 
using qRT-PCR. As indicated in Figure 4.11, while E2 resulted in an approximately 10-
fold increase in PR mRNA relative to control neither tamoxifen nor KC-3 displayed such 
a high increase in PR transcription, indicating that the binding of KC-3 to the ER, results 
in some agonistic activity, but not to the same extent as E2. A higher concentration of 
KC-3 may be required to cause significant PR downregulation. 
 
 
 
 
Figure 4.11 qrt-PCR for progesterone receptor (PR). Graph represents the fold 
difference in PR mRNA levels following 48 hr treatment of MCF-7 cells with DMSO, 
E2, KC-3 or TAM. The mRNA levels are quantified by normalization to β-actin. Data 
represent at least three replicates. 
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Activity of KC-7/dimeric PROTAC vs monomeric PROTACs KC-2, KC-6 and NC 
 A dimeric PROTAC was developed in order to determine whether a PROTAC 
strategy that uses two ligands is more efficient at targeting the ER than a monomeric one. 
The dimeric PROTAC was evaluated for its action on ER. Western blot analysis and 
immunofluorescence was used to analyze the abundance of ER following treatment with 
dimeric PROTAC.  Data revealed that the dimeric PROTAC had a significant effect on 
ER degradation in comparison to its monomeric counterparts; at 10 µM the dimer was 
capable of degrading relatively all the ER as indicated in Figure 4.12. The activity of the 
dimer also appear to be proteasome dependent,  as addition of the proteasome inhibitor 
epoxomicin (Epx) blocked the degradation of ER, as indicated by the 
immunofluorescence data (Figure 4.13). The effect of dimer on proliferation was also 
evaluated in Table 4.1 and the results indicated, surprisingly, that the dimer had no effect 
on proliferation at concentrations up to 200μM.  This may indicate that the dimer 
functions as an ER agonist as ER agonists are known to induce ER degradation in concert 
with transcriptional activationP [208]P. 
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Figure 4.12 Comparison of KC-7/dimeric PROTAC with monomeric KC-2, KC-6 
and NC. MCF-7 cells were with increasing concentrations of PROTACs DMSO or TAM 
(5 μM) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα 
antibody. The intensities of the bands on western blot films were quantified (%) using 
volumetric densitometry (Quantity One, Bio-Rad). The ERα values were normalized to β-
actin and DMSO was arbitrarily assigned a value of 100% for comparison purposes.  
 
 
 
 
 
 
 
A. 
B. 
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Figure 4.13:  Analysis of ER status via immunofluorescence following treatment 
with dimer PROTAC and proteasome inhibitor epoxomicin (Epx). MCF-7 cells were 
treated with DMSO or dimer or dimer and Epx for 48 hrs. Cells were then fixed on glass 
slides and treated with ERα monoclonal antibody, DAPI and secondary antibody FITC. 
Green (estrogen receptor-FITC), blue (DAPI nuclear stain). 
 
 
 
 
 
 
Copyright © Kedra C.Cyrus 2009 
 
10μM dimer 10μM dimer + Epx 
Media only 
97 
 
CHAPTER 5: CONCLUSIONS AND DISCUSSION 
 
5.1  Conclusions and discussion 
 The data contained herein provides a rational blueprint for the optimization of the 
design of an ER-targeting PROTAC. First, data obtained from the original E2-penta (O-
17 derivative) and C-16α PROTACs demonstrate that derivatizations at the C-16α 
position does not improve the ability of the PROTAC to degrade the ER when compared 
to the original PROTAC. While the presence of C-C bond instead of an ester bond may 
offer increased resistance to in vivo esterases, additional factors, such as binding affinity, 
are likewise essential for the judicious design of PROTACs. Interestingly, conjugation at 
the C-16α position showed efficient ER degradation for an E2-Geldanamycin hybridP [182]P, 
probably by disrupting the ER:HSP90 complex. However, the hybrid’s mode of action is 
not entirely clear. Consistent with our results, earlier works by Fevig et al. suggested that 
the tolerance for long, bulky substituents at the C-16α position is generally not highP [209]P. 
Nonetheless, the lesson from these C-16α PROTACs is that a benzyl protecting group at 
the C-terminal of the E3 ubiquitin ligase recognition motif enhances PROTAC activity 
compared to unprotected counterparts (Figure 3.4 and 3.5). It is believed that the benzyl 
group mimics the ODD region of HIF-1α, which is flanked by polypeptides and as such, 
the benzyl group may provide structural stability as well as protect the pentapeptide from 
peptidase attack.  
 Based on the conclusions drawn from the C-16α data, all remaining PROTACs 
were synthesized using the benzyl protected E3 ligase recognition motif. Several studies 
suggest that the C-7α position can be modified using long linkers without significant loss 
of ER binding affinity P [178, 203, 204, 205]P. Thus, we derivatized the C-7α position of estradiol 
to attach linkers of varying lengths for the optimization of the ER-targeting PROTAC.  
As Corson et al. point out, a linker has to be long enough to allow flexibility with 
the proper interactions between each moiety and its respective protein target, but short 
enough to allow for the proper interface between the two unitsP [210]P. This is in accordance 
with this data using C-7 derivatized PROTACs. Specifically, it has been shown here that 
linker length selection is crucial for promoting the desired PROTAC activity. A linker 
that is too short may generate steric hindrance between the two partner proteins, 
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preventing efficient ubiquitin transfer to the target. On the other hand, a linker that is too 
long may hinder the proper interaction between the E3 ubiquitin ligase and target protein.  
While PROTACs with nine and twelve atom linker length, KC-1 and KC-2, 
respectively, showed an ability to degrade the ER in a concentration dependent manner, 
they are considered less effective than KC-3.  Both KC-1 and KC-2 induced ER 
accumulation at low concentrations (500 nM), whereas KC-3, (16-atom length linker), 
did not induce significant accumulation of the ER at the concentrations tested. Overall, 
KC-3 was the most effective PROTAC as it induced potent ER degradation and 
successfully inhibited MCF-7 cell proliferation. Given that most ER regulated genes are 
associated with cell proliferation P [158]P, increased degradation of the ER by the PROTAC 
should elicit a lower expression of these genes, inhibiting cell proliferation. The 
effectiveness of the KC-3 PROTAC may be due its linker length, wherein the 16-atom 
spacer allows for the most effective interaction between ER and the E3 ligase complex. 
Another important lesson from these studies concerns the coupling of the ligand 
to the pentapeptide. Attachment of the small molecule ligand at the N-terminus of the 
HIF-1α pentapeptide is favored for PROTAC activity, as the activity of the PROTAC 
decreased when estradiol was attached at the C-terminus of the HIF-1α pentapeptide. 
Prior studies revealed a possible role for Tyr in enhancing the interaction of pVHL to the 
ODD, while other residues in the ODD were not essentialP [99]P. However, if the residue 
following Ile in the ODD sequence is considered, the Pro structure may be emulated by 
the benzyl ring at the C-ternimus of the pentapeptide.  Such homology might well 
account for the superiority of the N-terminal coupling.  
The negative control PROTAC (NC), in which, the critical hydroxy-proline is 
replaced with norleucine, did not induce ER degradation.  This is significant because its 
active counterpart, KC-2, effectively induces ER degradation. Replacement of the 
hydroxy-proline abrogrates the interaction between the HIF derived pentapeptide and the 
pVHL E3-ligase complex, which is essential for the action of the PROTAC.  
The synthesis of a dimeric PROTAC was undertaken in an attempt to improve the 
efficiency of the PROTAC strategy. The hypothesis for the design of the dimeric 
PROTAC was twofold; first, since dimerization of the ER is a consequence of ligand 
binding, association of a dimeric PROTAC with the ER could theoretically mirror this 
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process. Additionally, it was thought that the presence of two ligands on either end of the 
HIF pentapeptide should increase the likelihood of an interaction between the PROTAC 
and ER. As shown in Figure 4.11, administration of the dimer resulted in very effective 
ER degradation at concentrations lower than either of its corresponding monomeric 
halves, KC-2 and KC-6.  
However, the enhanced ER degradation by dimer did not translate to an effect on 
MCF-7 cell proliferation, as demonstrated by the high ICR50 Rvalue (Table 4.1). This result 
is similar to a previous study conducted using estrone dimers. The estrone dimers were 
incapable of inhibiting breast cancer cell proliferation and displayed ICR50 Rvalues similar 
to E2 (>200 μM), leading the authors to postulate that the dimers may function as an E2-
like compoundP [200]P. This is a reasonable justification of the data seen with the dimeric 
PROTAC, as it too displayed no effect on MCF-7 cell proliferation. 
 There are a few likely rationales for this discrepancy between the monomeric and 
dimeric PROTACs.  The first point to consider is that the dimeric PROTAC may bind 
either to one ER or to a pair of ERs, resulting in their dimerization.  Dimer binding to a 
pair of ERs may thus result in agonistic activity similar to the binding of the cognate 
ligand. Binding of the cognate ligand results in transcriptional activation of target genes a 
process that requires degradation of the ERP [208]P. Likewise, since the linker between each 
E2 and the HIF-1α pentapeptide is 12 atoms, its inherent flexibility might promote 
conformational changes that impede the interaction between the pentapeptide and the E3 
ligase. This hindrance of E3-PROTAC interaction would effectively prevent the pVHL-
mediated ubiquitination and degradation of the ER, while likely leading to transcriptional 
activation of target genes and subsequent degradation of the ER. . 
While the current dimer PROTAC did not have many advantageous properties, 
the binding affinity experiment clearly indicates that the dimer has high affinity for the 
ER. This demonstrates the potential for a dimeric PROTAC approach to effectively bind 
a target protein, which may result in the efficient recruitment of the target protein to the 
E3 ubiquitin ligase. To further validate the dimeric PROTAC approach, a dimeric 
PROTAC that uses tamoxifen (antagonist) instead of the agonist (estradiol) should be 
explored. This will eliminate the agonistic activity of the dimeric PROTAC that was 
observed in this study. To conclusively determine the mode of action of the dimeric 
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PROTAC, a negative control dimer should be prepared as well. Additionally, analogous 
to what was done for the monomeric PROTACs, it will be interesting to develop dimers 
with varying spacers to assess the optimal linker for a dimeric PROTAC. 
Therefore, the general conclusions that can be made from these studies are as 
follows: 
1. An optimum ER-targeting monomeric PROTAC (KC-3) has a spacer of about 
16 atoms between the E2, attached at the C-7α position, and the HIF-1α 
pentapeptide attached at the N-terminus. 
2. The monomeric PROTAC is capable of targeting the ER for degradation in a 
proteasome- and pVHL-dependent manner. 
3. The optimal PROTAC (KC-3) inhibits proliferation of MCF-7 cells with an 
ICR50 Rsimilar to that of tamoxifen. 
4. KC-3 alone does not induce the transcription of PR, a downstream target of 
the ER, to the same extent as E2. 
5. A dimeric PROTAC binds the ER, induces ER degradation and functions in a 
proteasome dependent manner, but more studies are needed to validate the 
dimeric PROTAC approach. 
 
 
5.2  UFuture directions: 
 
 While this project has provided a great deal of information about the overall 
design of an ER-targeting PROTAC, there are still some avenues that are currently 
unexplored. For example, what is the potential of an ER-targeting PROTAC as a 
therapeutic agent? The effect of ER-targeting PROTACs has only been analyzed in MCF-
7 cell lines. An analysis of the actions of PROTAC in other ER expressing cells or tissues 
such as the uterus and bone should be undertaken in the future to decide whether 
PROTAC activity varies from one tissue to the other. This is essential information to 
obtain prior to the consideration of an ER-targeting PROTAC as a therapeutic agent.  
Also,  in terms of therapeutic value, an ER-targeting PROTAC could be of tremendous 
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benefit in cases where resistance to tamoxifen and other antiestrogens have developed, as 
the ER is still present and functional in cases of resistance; therefore the activity of KC-3 
in tamoxifen/antiestrogen resistant cells should be evaluated.   
Additionally, the effect of other ER ligands, such as tamoxifen and genistein 
(phytoestrogen) among others, should be explored. Tamoxifen is a known SERM that 
binds the ER and displays both antagonistic and agonistic activities depending on its 
tissue binding, whereas genistein is a flavone that binds the ER and induce estrogen-like 
activities. The mechanism of PROTAC activity currently presumes that any ligand 
capable of binding the ER should engender a stable complex facilitating the 
ubiquitination and degradation of the ER. Showing that any ligand capable of binding the 
ER can target the protein for degradation in a PROTAC-dependent manner will further 
strengthen the idea of the approach.  
A major drawback to the PROTAC approach as it is utilized currently is the 
inclusion of a peptide moeity.  The pentapetide as the E3-ligase recognition motif may be 
subjected to peptidase activity in vivo, thus replacement of the pentapeptide with a non-
peptide moiety such as a peptidomimetic or a small molecule may be useful in future 
design of a PROTAC. This change in the structure of the PROTAC may require a 
reoptimization of the linker length. 
One of the goals in undertaking this study was to provide a potential blueprint for 
the design of PROTACs targeting other proteins. From the studies conducted up to this 
point, a few generalizations can be made.  First, the PROTAC has been shown to be a 
tool that can be used to target any protein with a known ligand specifically to the UPS for 
degradation. Secondly, these studies demonstrate that a pentapeptide derived from HIF-
1α is sufficient for the activity of these PROTACs. Additionally, both the location of the 
attachment to the linker and length of the linker moiety are critical for the optimization of 
the PROTAC design. A sixteen atom linker proved to be optimal for a monomeric ER-
targeting PROTAC; however, more experiments should be conducted to ascertain 
whether this linker length will be generally applicable in the design of PROTACs 
targeting other proteins.   
More specifically, the design of the ER-targeting PROTAC may provide some 
insights for the design of other PROTACs targeting nuclear receptors, as they are 
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structurally similar to the ER.  Still, adjustments will likely be required to accommodate 
the specific ligands for these other protein targets. However, because of the high 
homology within the nuclear receptor family, the ER-PROTAC may provide a good 
starting point for the design of other nuclear receptor-targeting PROTACs.  
Overall, the PROTAC approach could be a useful strategy for probing proteins 
with known ligands.  More studies need to be done using the current model to develop 
PROTACs that target other proteins to validate the general application of this strategy. 
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